Access to Electron-Deficient 2,2-Disubstituted Chromanes: A Highly Regioselective One-Pot Synthesis via an Inverse-Electron-Demand [4 + 2] Cycloaddition of *ortho*-Quinone Methides

Kenta Tanaka,[®] Mami Kishimoto, Yosuke Asada, Yuta Tanaka, Yujiro Hoshino,*[®] and Kiyoshi Honda*

Graduate School of Environment and Information Sciences, Yokohama National University, Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan





ABSTRACT: We report the one-pot synthesis of 2,2-disubstituted chromanes with electron-withdrawing substituents. This reaction provides a simple yet efficient route to a wide range of electron-deficient chromanes in high yield and excellent regioselectivity. The reaction of salicylaldehyde with 1,1-disubstituted ethylenes smoothly furnishes these electron-deficient chromanes, which can be further transformed into functionalized chromanes or chromene. For example, **BW683C** was effectively synthesized from 5-chlorosalicylaldehyde with 4-chlorostyrene in two steps in excellent yield. The present reaction thus provides versatile access to functionalized electron-deficient chromanes and chromenes and therefore constitutes a promising tool for the synthesis of biologically and photochemically active molecules.

INTRODUCTION

Owing to their unique biological properties, the development of efficient synthetic methods for chromanes has attracted significant attention in organic chemistry and medicinal science.¹ Most biologically active chromanes contain multiple substituents, especially electron-donating moieties such as the methoxy group.¹ Based on the characteristic features of these compounds, a number of research groups have explored the synthesis of chromanes that bear electron-donating moieties (Scheme 1a).² In comparison, chromanes substituted with electron-withdrawing groups have received substantially less attention. Some chromanes that bear electron-withdrawing substituents exhibit biological (for example, antirhinoviral, antihypertensive, and antimicrobial) activity (Figure 1).³ Despite the number of reports on these functionalized chromanes, the synthesis of such electron-deficient compounds has been much less explored. In addition, the previously reported synthetic methods suffer from requirements such as laborious reaction procedures and functionalization with strongly electron-withdrawing groups.^{3,4} Recently, Ohwada and co-workers have demonstrated that 4H-1,2-benzoxazines with various electron-withdrawing substitutes react with ethylenes to furnish the corresponding chromanes.⁵ This sequence successfully provides chromanes that bear strongly electron-withdrawing groups such as NO₂, CN, and CF₃.

We have previously developed an acid-catalyzed synthesis of *ortho*-quinone methides (*o*-QMs) from salicylaldehyde in the presence of trimethyl orthoformate under mild conditions.⁶ During that study, we investigated the inverse-electron-demand [4 + 2] cycloaddition reaction of in situ-generated strongly electron-withdrawing *o*-QMs with arylalkynes, which afforded 2*H*-chromenes.⁷ To expand the access to chromanes with electron-withdrawing substituents, we report herein a highly regioselective one-pot synthesis of electron-deficient 2,2-disubstituted chromanes using easily available substrates (Scheme 1b). This reaction provides a simple yet efficient route to a wide range of electron-deficient chromanes.

RESULTS AND DISCUSSION

Initially, we screened the reaction of 5-nitrosalicylaldehyde (1a) with 1,1-diphenylethylene (2a) using a variety of acid

Received: July 25, 2019 **Published:** October 3, 2019 Article

pubs.acs.org/joc

Article

Scheme 1. Synthesis of Chromanes with Various Substituents

(a) chromanes with electron-donating substituents (previous work)





Figure 1. Selected examples of bioactive chromanes with electronwithdrawing substituents.

catalysts and solvents at room temperature (Table 1). When polar solvents such as dimethylformamide (DMF) and MeOH were used in the presence of catalytic amounts of trifluoromethanesulfonic acid (TfOH; 20 mol %), the reaction did not afford any of the targeted products (entries 1 and 2). However, CH₃CN efficiently promotes the reaction, providing the desired chromane (**3a**) in 69% yield (entry 3). In addition, moderately polar to nonpolar solvents such as tetrahydrofuran (THF), CH₂Cl₂, and toluene are also suitable (entries 4–6), whereby especially toluene effectively increased the product yield to 85%. Other Brønsted acids did not efficiently provide the product (entries 7–13).⁸ Subsequently, we confirmed that the strong Brønsted acid TfOH smoothly promotes the

Table 1. Optimization of the Reaction Conditions^a



entry	catalyst	solvent	yield (%) ^b
1	TfOH	MeOH	nr ^c
2	TfOH	DMF	nr ^c
3	TfOH	CH ₃ CN	69
4	TfOH	THF	25
5	TfOH	CH_2Cl_2	79
6	TfOH	toluene	85
7	PhSO ₃ H	toluene	32
8	MeSO ₃ H	toluene	15
9	p-TsOH·H₂O	toluene	8
10	$HBF_4 \cdot OEt_2$	toluene	18
11	TFA	toluene	nr ^c
12	CSA ^d	toluene	nr ^c
13	PhCO ₂ H	toluene	nr ^c
14	$Pd(OAc)_2$	toluene	nr ^c
15	$Sc(OTf)_3$	toluene	15
16	$Al(OTf)_3$	toluene	26
17	$BF_3 \cdot OEt_2$	toluene	trace
18 ^e	TfOH	toluene	71
19 ^f	TfOH	toluene	63
20 ^g	TfOH	toluene	0

^{*a*}All reactions were carried out using **1a** (0.5 mmol), **2a** (1.5 mmol), CH(OMe)₃ (1.0 mmol), and the corresponding catalyst (20 mol %) in the specified solvent (5.0 mL) at room temperature for 1 h. ^{*b*}Isolate yield. ^{*c*}nr: no reaction. ^{*d*}CSA: (+)-10-camphorsulfonic acid. ^{*e*}Amount of **2a**: 1.0 mmol. ^{*f*}Amount of TfOH: 10 mol %. ^{*g*}From room temperature (1 h) to 100 °C (1 h).

generation of an *o*-QM from salicylaldehyde **1a**. The use of $Pd(OAc)_2$, which is a soft Lewis acid, was not successful (entry 14), while $Sc(OTf)_3$, which is a hard Lewis acid catalyst that has been used in the [4 + 2] cycloaddition of salicylaldehydes

with ethylenes by Yadav and co-workers,⁹ affords the product in 15% yield (entry 15). TfOH is an inexpensive organic catalyst that is much easier to handle than $Sc(OTf)_3$. Other hard Lewis acid catalysts afforded low product yields (entries 16 and 17), while decreasing the amounts of **2a** or TfOH did not improve the product yield (entries 18 and 19). Next, we examined the effect of reaction temperature on the yield. When the reaction mixture was initially stirred at room temperature (1 h) and then heated to 100 °C (1 h), 4-alkenylchromane **4a** was obtained in 74% yield instead of 4-methoxychromane **3a** (entry 20, Figure 2). This result suggests that the elimination



Figure 2. 4-Alkenylchromane 4a.

of the methoxy group from chromane **3a** under acidic conditions at 100 °C furnishes a dihydropyrylium salt, which could react with 1,1-disubstituted ethylene to yield the corresponding 4-alkenylchromane. This synthetic strategy constitutes a new method to control the formation of carbon–carbon or carbon–oxygen bonds via controlling the reaction temperature. The thus-obtained chromanes, which contain carbon–carbon or carbon–oxygen bonds at the 4-position, represent important structural motifs in natural products and medicinal chemistry.¹⁰ Against this background, we examined the scope of this selective, direct, and temperature-controlled synthetic route to 4-alkoxy and 4-alkenylchromanes.

With the optimized conditions in hand, we examined the scope and limitations of the formation of 4-methoxychromanes and 4-alkenylchromanes (Table 2). Salicylaldehydes with strongly to moderately electron-withdrawing groups were well tolerated, under both conditions A and B (3a-f, 4a-f). 2-Hydroxy-1-naphthoaldehyde furnished 3g together with chromene 5g as an inseparable mixture in 33 and 32% yields, respectively. When the quantitative ratio of the starting materials was optimized (1/2 = 2:1), chromene 5g was selectively obtained in 66% yield. Chromene 5g is a photochromic material,¹¹ which suggests that the present method may also represent a facile and efficient one-pot approach to the synthesis of chromene-based photochromic materials from easily available starting materials.¹² In addition, high yield was obtained under condition B (4g). The parent salicylaldehyde is also a good substrate for the formation of chromanes 3h and 4h. The 1,1-diphenylethylene with *p*-chloro groups afforded the corresponding products (3i and 4i) in good yield. The reaction using a 1,1-dialkylethylene, that is, 1methyl-1-phenylethylene, proceeded under condition A (3j and 3k).^{10,13,14} Interestingly, spiro compounds were obtained when 9-methylene-9H-thioxanthene and 5-methylene-5Hdibenzo[a,d][7]annulene were used as the dienophile (31 and 3m). Styrene was also a good substrate under condition A,¹⁴ suggesting that the reaction can be applied to not only 1,1disubstituted olefins but also monosubstituted ones. Diarylethylenes were suitable under condition B, while other ethylenes furnished complex mixtures (4j-n), which suggests

that the bisphenyl groups may effectively stabilize the benzyl cation of the intermediate (vide infra). 15

Subsequently, we examined the corresponding reactions between acetophenones and salicylaldehydes. Under acidic conditions, in the presence of trimethyl orthoformate, acetophenone A is converted into 1-methoxy-1-phenyl ethylene C via acetal B (Scheme 2).¹⁶ Initially, when 4'nitroacetophenone was treated with 5-nitrosalicylaldehyde, the desired cycloadduct (6a) was obtained in high yield (Table 3). Although acetophenones that bear strongly electronwithdrawing groups are usually unsuitable dienophile substrates for inverse-electron-demand Diels-Alder reactions, this reaction proceeded smoothly to give the desired chromanes.¹⁷ This may tentatively be ascribed to the fact that the methoxy group on ethylene C (Scheme 2) effectively promotes the reaction as an electron-donating group. Fortunately, single crystals suitable for an X-ray diffraction analysis were obtained, from which the relative stereochemistry of cis- and transchromanes 6a was determined.¹⁸ The separation of cis/trans isomers can be achieved by column chromatography, and the isolated ratio is shown in Table 3. When we examined the use of 3 equiv (excess) of acetophenone, the mixture of the desired product and acetophenone could not be completely separated by column chromatography. Therefore, we examined the amount of salicylaldehyde used, and optimal results were obtained for 2 equiv, that is, the consumption of acetophenone was virtually complete and only the desired chromane was isolated. 4'-Nitrileacetophenone also readily undergoes this transformation (6b). Halogen-functionalized derivatives are also good substrates to afford 6c-e. Salicylaldehydes that bear strongly to moderately electron-withdrawing groups also furnished the corresponding cycloadducts in good yield (6fk). The parent salicylaldehyde was also suitable for the reaction (61). It is noteworthy that this reaction is applicable to various substrates with electron-withdrawing groups, which stereoselectively give electron-deficient 2,2-disubstituted chromanes.

Further transformations of chromane 3a are shown in Scheme 3. When 3a was treated with TsNH₂ in the presence of FeCl₃, 4-aminochromane 7a was obtained in high yield. Moreover, the reaction of 3a with allyltrimethylsilane afforded 4-alkylchromane 8a. 4-Amino- and 4-alkylchromanes are found in natural products and biologically active compounds, with, for example, antimicrobial, potassium-channel-opening, and other bio-organic properties.^{3,19} The hydrogenation of 3a furnished 6-aminochromane 9a in good yield. 6-Aminochromanes also exhibit diverse bioactivity.²⁰ Interestingly, when 3a was treated with N-bromosuccinimide (NBS), 3bromochromene 10a was obtained in 75% yield. This reaction thus provides a new synthetic route to 3-bromochromenes,²¹ which may lead to photochromic 2,2,3-triaryl-2H-chromenes.²² It should be noted here that this reaction represents a feasible route to chromenes, leading to the effective synthesis of photochemically active molecules. For example, BW683C is a highly effective inhibitor of the replication of certain serotypes of rhinovirus.^{3a} Recently, the synthesis of BW683C has been reported, including a modular synthesis of 2-alkyl- and 2arylchromans via a three-step sequence and a regioselective domino synthesis of 2-alkylflavans via a hidden Brønsted acid catalysis.²³ To demonstrate the synthetic utility of the method presented herein, we synthesized BW683C in two steps in 90% yield from 5-chlorosalicylaldehyde with 4-chlorostyrene (Scheme 4). It should be noted here that this method is

Table 2. Synthesis of 4-Methoxychromanes 3 and 4-Alkenylchromanes 4^e



^{*a*}A complex mixture was obtained. ^{*b*}Salicylaldehyde (2.0 mmol) and the 1,1-disubstituted ethylene (1.0 mmol) were stirred for 24 h. The product yield is given with respect to the ethylene. ^{*c*}¹H NMR yield. ^{*d*}Salicylaldehyde (2.0 equiv) and ethylene (1.0 equiv) were reacted for 6 h. The product yield was calculated on the basis of the ethylene. ^{*e*}Condition A: **1** (0.5 mmol), **2** (1.5 mmol), CH(OMe)₃ (1.0 mmol), and TfOH (20 mol %) in toluene (5.0 mL) at room temperature for 1 h; condition B: **1** (0.5 mmol), **2** (1.5 mmol), CH(OMe)₃ (1.0 mmol), and TfOH (20 mol %) in toluene (5.0 mL) at room temperature (1 h) and then at 100 °C (1 h).

Scheme 2. Generation of 1-Phenyl-1-methoxy Ethylene C in the Presence of an Acid Catalyst



based on easily available substrates and inexpensive catalysts and provides the products in excellent yield. 3a,23

A mechanism for the present reaction is proposed in Scheme 5. An *o*-QM is generated from salicylaldehyde **12** with trimethyl orthoformate via acetal **13** under acidic conditions. An inverse-electron-demand Diels–Alder reaction of the *o*-QM with a 1,1-disubstituted ethylene (**14**) affords chromane **15**, probably via a concerted mechanism and an endo addition.^{13,14,24} The formation of 4-alkenylchromane **4a** from 4-methoxychromane **3a** under the reaction conditions outlined in Scheme 6 (1) strongly suggests that the retro-Diels–Alder reaction occurs at 100 °C and regenerates the starting compounds *o*-QM and 1,1-diphenylethylene in situ [Scheme

Table 3. Reaction of Acetophenones with Salicylaldehydes^a



^aThe ratio of cis/trans isomers was determined by ¹H NMR spectroscopy. ^bReaction conducted at 40 °C for 24 h.







Scheme 5. Proposed Mechanism for the Reaction of Salicylaldehyde (12) with 1,1-Disubstituted Ethylenes



6 (2)]. The elimination of the methoxy group on chromane 15 under acidic conditions would then afford cationic intermediate 16, before 17 could be generated via either path A or B. Intermediate 16 could be attacked from the exo side of the dihydrobenzopyrylium ring by the 1,1-disubstituted ethylene to yield the stable dibenzyl cation 17 (path A).²⁵ Dihydropyrylium 16 could also react with the 1,1-disubstituted ethylene via an endo approach to give 17 (path B).²⁶ Based on density functional theory (DFT) calculations at the theoretical level of B3LYP with the 6-31G(d,p) basis set, path A might be energetically more favorable than path B.²⁷ Finally, the loss of a proton from 17 would afford the desired product (18). Further

Е

Scheme 6. Reaction of Chromane 3a in the Absence of 1,1-Diphenyl Ethylenes



studies on the scope and mechanism of this reaction are currently in progress and will be reported in due course.

CONCLUSIONS

We have developed a highly regioselective one-pot method for the generation of electron-deficient 2,2-disubstituted chromanes via an inverse-electron-demand [4 + 2] cycloaddition. When 1,1-disubstituted ethylenes or acetophenones are reacted with salicylaldehydes that bear electron-withdrawing groups, the desired chromanes are obtained in high yield and excellent regioselectivity. The reaction of salicylaldehydes with 1,1-disubstituted ethylenes generates 4-methoxychromanes at room temperature, whereas 4-alkenylchromanes are obtained when the reaction is carried out at room temperature and then at 100 °C. Further transformations of the electron-deficient chromanes furnished functionalized chromanes or chromene. For example, BW683C was synthesized from 5-chlorosalicylaldehyde and 4-chlorostyrene in 90% yield in two steps. The present reaction thus provides versatile access to functionalized electron-deficient chromanes and chromenes and therefore constitutes a promising tool for the synthesis of biologically and photochemically active molecules.

EXPERIMENTAL SECTION

General Information. Infrared (IR) spectra were recorded on JASCO FT/IR-4100. ¹H NMR spectra were recorded on a Bruker DRX-300 (300 MHz) spectrometer, a Bruker DRX-500 (500 MHz) spectrometer, or a JEOL ECA-500 (500 MHz) spectrometer with tetramethylsilane (TMS) as the internal standard. Chemical shifts are reported in ppm relative to TMS (δ 0). NMR data are reported as follows: chemical shift, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constants, integration. $^{13}\mathrm{C}\{^{1}\mathrm{H}\}$ NMR spectra were recorded on a Bruker DRX-500 (126 MHz) spectrometer or a JEOL ECA-500 (126 MHz) spectrometer under complete proton decoupling. Chemical shifts are reported in ppm relative to the solvent resonance of CDCl₃ (δ 77.0). High-resolution mass spectra (HRMS) were recorded on a Hitachi High-Technologies Nanofrontier LD Spectrometer [electrospray ionization (ESI)/timeof-flight]. Column chromatography was carried out on Cica-reagent silica gel 60 N (spherical; particle size: $63-210 \ \mu m$). Thin-layer chromatography (TLC) was carried out on Merck TLC plates with silica gel (60 F₂₅₄). Single-crystal X-ray diffraction analyses were performed at 223 K using a Rigaku XtaLAB P200 diffractometer with a graphite-monochromated Cu K α radiation (λ = 1.54187 Å). Unless otherwise noted, commercially purchased reagents were used as received. 1,1-Disubstituted ethylenes were prepared according to published methods.²⁸

1,1-Bis(4-chlorophenyl)ethylene. Yellow solid (572.1 mg, 77% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.35–7.20 (m, 8H), 5.45 (s, 2H). The spectroscopic data were consistent with literature values.³³

1,1-Bis(3-fluorophenyl)ethylene. Yellow oil (455.3 mg, 13% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.34–7.27 (m, 2H), 7.13–7.07 (m, 2H), 7.05–7.00 (m, 4H), 5.51 (s, 2H). The spectroscopic data were consistent with literature values.³⁴

1,1-Bis(4-methoxyphenyl)ethylene. White solid (1.0934 g, 91% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.30–7.24 (m, 4H), 6.90–6.83 (m, 4H), 5.29 (s, 2H), 3.83 (s, 6H). The spectroscopic data were consistent with literature values.³⁵

2-Heptyl-1-nonene. Colorless liquid (742.3 mg, 66% yield). ¹H NMR (300 MHz, CDCl₃): δ 4.68 (s, 2H), 1.99 (t, *J* = 6.8 Hz, 4H), 1.46–1.36 (m, 4H), 1.28 (m, 16H), 0.88 (t, *J* = 7.2 Hz, 6H). The spectroscopic data were consistent with literature values.³²

9-Methylene-9H-thioxanthene. Yellow solid (143.6 mg, 15% yield). ¹H NMR (500 MHz, $CDCl_3$): δ 7.65–7.61 (m, 2H), 7.37–7.34 (m, 2H), 7.28–7.24 (m, 4H), 5.55 (s, 2H). The spectroscopic data were consistent with literature values.³⁶

5-Methylene-5H-dibenzo[a,d][7]annulene. White solid (685.5 mg, 73% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.42–7.23 (m, 8H), 6.83 (s, 2H), 5.26 (s, 2H). The spectroscopic data were consistent with literature values.³⁷

General Procedure for the Synthesis of Chromanes. Synthesis of Chromane 3. Salicylaldehyde 1 (0.50 mmol), 1,1disubstituted ethylene 2 (1.5 mmol), and trimethyl orthoformate (1.0 mmol) were dissolved in dry toluene (5.0 mL) under an atmosphere of nitrogen before trifluoromethanesulfonic acid (20 mol %) was added to the reaction mixture. After stirring at room temperature for 1 h, the reaction mixture was neutralized with 5% aqueous (aq) NaHCO₃. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5.0 mL × 3). The combined organic phases were washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 50/ 1, v/v) to afford chromane 3.

Synthesis of Chromane 4. Salicylaldehyde 1 (0.50 mmol), 1,1disubstituted ethylene 2 (1.5 mmol), and trimethyl orthoformate (1.0 mmol) were dissolved in dry toluene (5.0 mL) under an atmosphere of nitrogen before trifluoromethanesulfonic acid (20 mol %) was added to the reaction mixture. After stirring at room temperature for 1 h, the reaction mixture was heated to 100 °C (oil bath) and stirred for 1 h. Then, every 15 min, a three-way stopcock was carefully opened three times to quickly discharge gaseous methanol. After the reaction was completed, the reaction mixture was neutralized with 5% aq NaHCO₃. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5.0 mL \times 3). The combined organic phases were washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane) to afford chromane 4.

Synthesis of Chromane 6. Salicylaldehyde 1 (2.0 mmol), acetophenone 2 (1.0 mmol), and trimethyl orthoformate (4.0 mmol) were dissolved in dry toluene (5.0 mL) under an atmosphere of nitrogen before trifluoromethanesulfonic acid (20 mol %) was added to the reaction mixture. After stirring at room temperature for 1.5 h, the reaction mixture was neutralized with 5% aq NaHCO₃. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5.0 mL \times 3). The combined organic phases were washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 20/1, v/v) to afford chromane 6.

Characterization Data for the Chromanes. *4-Methoxy-6nitro-2,2-diphenylchromane* (*3a*). 5-Nitrosalicylaldehyde (84.3 mg, 0.50 mmol), 1,1-diphenylethylene (264 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). Yellow solid (154.2 mg, 85% yield). ¹H NMR (300 MHz, CDCl₃): δ 8.30 (dd, *J* = 2.8, 0.9 Hz, 1H), 8.13 (dd, *J* = 9.0, 2.6 Hz, 1H), 7.45–7.27 (m, 10H), 7.14 (d, *J* = 9.0 Hz, 1H), 4.28 (dd, *J* = 10.9, 5.7 Hz, 1H), 3.54 (s, 3H), 3.34 (dd, *J* = 13.4, 5.5 Hz, 1H), 2.46 (dd, *J* = 13.4, 10.7 Hz 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 158.8, 144.1, 141.9, 141.7, 128.9, 128.4, 128.0, 127.8, 125.8, 125.7, 125.0, 124.3, 124.1,

117.5, 84.4, 71.1, 56.5, 36.3; IR [attenuated total reflection (ATR)]: 1585, 1516, 1478, 1432, 1338, 1253, 1098, 1081, 1017, 900, 752, 697 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{22}H_{19}NO_4Na$ ([M + Na]⁺): 384.1206, found: 384.1226.

4-Methoxy-2,2-diphenyl-6-tosyloxychromane (**3b**). 2-Hydroxy-5tosyloxybenzaldehyde (145.4 mg, 0.50 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (226.9 mg, 94% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.66 (d, *J* = 7.6 Hz, 2H), 7.43–7.37 (m, 4H), 7.35–7.22 (m, 8H), 6.97 (dd, *J* = 3.0, 0.8 Hz, 1H), 6.92 (d, *J* = 8.9 Hz, 1H), 6.80–6.75 (m, 1H), 4.21 (dd, *J* = 10.9, 5.7 Hz, 1H), 3.35 (s, 3H), 3.19 (dd, *J* = 13.2, 5.7 Hz, 1H), 2.48–2.36 (m, 4H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 152.2, 145.0, 144.9, 143.0, 142.5, 132.4, 129.6, 128.6, 128.5, 128.2, 127.6, 127.4, 126.0, 125.6, 124.3, 122.9, 121.2, 117.6, 83.0, 71.2, 55.6, 36.2, 21.6; IR (ATR): 1486, 1449, 1364, 1173, 1132, 1091, 1026, 943, 892, 838, 808, 735, 663 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₉H₂₆O₃NaS ([M + Na]⁺): 509.1393, found: 509.1383.

4-Methoxy-6-methoxycarbonyl-2,2-diphenylchromane (**3c**). Methyl 3-formyl-4-hydroxybenzoate (90.4 mg, 0.50 mmol), 1,1diphenylethylene (264 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). White solid (156.8 mg, 83% yield). ¹H NMR (500 MHz, CDCl₃): δ 8.07 (s, 1H), 7.91 (d, *J* = 8.5 Hz, 1H), 7.47–7.40 (m, 4H), 7.35–7.19 (m, 6H), 7.09 (d, *J* = 8.5 Hz, 1H), 4.29 (dd, *J* = 10.4, 5.7 Hz, 1H), 3.83 (s, 3H), 3.48 (s, 3H), 3.28 (dd, *J* = 13.2. 5.4 Hz, 1H), 2.50–2.546 (m, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 166.7, 157.5, 144.7, 142.4, 130.7, 129.6, 128.6, 128.3, 127.7, 127.5, 125.9, 125.7, 123.3, 122.7, 117.0, 83.4, 71.4, 56.1, 51.7, 36.5; IR (ATR): 1707, 1585, 1493, 1448, 1296, 1262, 1212, 1117, 1093, 1025, 928, 766, 708 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₂₄H₂₂O₄Na ([M + Na]⁺): 397.1410, found: 397.1415.

6-Bromo-4-methoxy-2,2-diphenylchromane (**3d**). 5-Bromosalicylaldehyde (99.7 mg, 0.50 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (219.7 mg, quant.). ¹H NMR (300 MHz, CDCl₃): δ 7.47–7.38 (m, 5H), 7.38–7.16 (m, 8H), 6.94 (d, *J* = 8.7 Hz, 1H), 4.26 (dd, *J* = 10.6, 5.7 Hz, 1H), 3.48 (s, 3H), 3.24 (dd, *J* = 13.4, 5.8 Hz), 2.44 (dd, *J* = 13.4, 10.7 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 152.7, 145.0, 142.5, 132.0, 130.0, 128.7, 128.3, 127.7, 127.5, 126.1, 125.8, 125.4, 118.8, 113.0, 83.0, 71.5, 56.1, 36.5; IR (ATR): 1474, 1264, 1217, 1100, 1060, 1020, 915, 888, 829, 699 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₂H₁₉O₂Na⁷⁹Br ([M + Na]⁺): 417.0461, found: 417.0451.

4-Methoxy-2,2-diphenyl-7-tosyloxychromane (**3e**). 2-Hydroxy-4tosyloxybenzaldehyde (84.3 mg, 0.49 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (210.6 mg, 88% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.70 (d, *J* = 8.2 Hz, 2H), 7.40–7.35 (m, 4H), 7.32–7.26 (m,6H), 7.25–7.19 (m, 3H), 6.73–6.69 (m, 1H), 6.54 (d, *J* = 8.5 H, 1H), 4.23 (dd, *J* = 10.4, 5.4 Hz, 1H), 3.43 (s, 3H), 3.22 (dd, *J* = 11.8, 5.8 Hz, 1H), 2.45–2.38 (m, 4H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 154.1, 149.7, 145.2, 144.7, 142.4, 132.3, 129.6, 128.5, 128.5, 128.2, 128.2, 127.6, 127.4, 126.0, 125.6, 122.4, 114.6, 110.8, 83.2, 71.3, 56.0, 36.5, 21.6; IR (ATR): 1594, 1492, 1370, 1191, 1177, 1110, 1090, 963, 811, 698 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₉H₂₆O₅NaS ([M + Na]⁺): 509.1393, found: 509.1393.

7-Bromo-4-methoxy-2,2-diphenylchromane (**3f**). 4-Bromosalicylaldehyde (84.3 mg, 0.51 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). Yellow solid (157.1 mg, 78% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.42 (m, 4H), 7.34–7.29 (m, 4H), 7.27–7.21 (m, 3H), 7.18 (dd, *J* = 8.2, 1.0 Hz, 1H), 7.02 (dd, *J* = 8.2, 1.9 Hz, 1H), 4.25 (dd, *J* = 10.7, 5.7 Hz, 1H), 3.45 (s, 3H), 3.23 (dd, *J* = 13.6, 5.7 Hz, 1H), 2.44 (dd, *J* = 13.6, 10.7 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 154.4, 144.9, 142.5, 128.7, 128.3, 127.7, 127.5, 126.1, 125.7, 123.9, 122.4, 122.0, 119.9, 83.2, 71.4, 55.9, 36.6; IR (ATR): 1598, 1477, 1406, 1225, 1090, 1016, 814, 700 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₂₂H₁₉O₂Na⁷⁹Br ([M + Na]⁺): 417.0461, found: 417.0449. 2,3-Dihydro-1-methoxy-3,3-diphenyl-1H-naphto[2,1-b]pyran (**3g**). 2-Hydroxy-1-naphthaldehyde (86.1 mg, 0.50 mmol), 1,1-diphenylethylene (264 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). White solid (61.0 mg, 33% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.87 (d, J = 8.7 Hz, 1H), 7.74–7.70 (m, 2H), 7.53–7.39 (m, 5H), 7.33–7.14 (m, 8H), 4.97 (t, J = 6.6 Hz, 1H), 3.39 (s, 3H), 3.21–3.13 (m, 1H), 3.07–2.99 (m, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 152.4, 144.7, 143.5, 132.8, 130.5, 129.5, 128.4, 128.3, 128.1, 127.4, 127.2, 126.5, 126.3, 125.8, 123.9, 123.4, 119.3, 114.1, 82.1, 69.9, 54.2, 36.5; IR (ATR): 1737, 1624, 1446, 1233, 1215, 1095, 1079, 1060, 908, 814, 733, 696 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₆H₂₂O₂Na ([M + Na]⁺): 389.1512, found: 389.1522.

4-Methoxy-2,2-diphenylchromane (**3h**). Salicylaldehyde (48.3 μL, 0.50 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (131.5 mg, 83% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.52–7.39 (m, 4H), 7.35–7.18 (m, 8H), 7.05 (dd, *J* = 8.3, 1.1 Hz, 1H), 6.90 (t, *J* = 7.4 Hz, 1H), 4.33 (dd, *J* = 10.6, 5.7 Hz, 1H), 3.47 (s, 3H), 3.24 (dd, *J* = 13.6, 5.7 Hz, 1H), 2.49 (dd, *J* = 13.2, 10.6 Hz, 1H); $^{13}C{^1H}$ NMR (126 MHz, CDCl₃): δ 153.6, 145.4, 143.0, 129.0, 128.5, 128.2, 127.4, 127.3, 127.2, 126.2, 125.8, 123.2, 120.7, 116.9, 82.5, 71.8, 55.8, 36.8; IR (ATR): 1581, 1486, 0445, 1228, 1216, 1096, 1020, 757, 700 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₂H₂₀O₂Na ([M + Na]⁺): 339.1356, found: 339.1360.

2,2-Bis(4-chlorophenyl)-4-methoxychromane (**3***i*). Salicylaldehyde (48.3 μ L, 0.50 mmol), 1,1-bis(4-chlorophenyl)ethylene (373.7 mg, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). White solid (122.1 mg, 63% yield). ¹H NMR (300 MHz, CDCl₃): δ 7.40–7.32 (m, 5H), 7.32–7.23 (m, 5H), 7.20 (dt, *J* = 7.3, 0.9 Hz, 1H), 7.03 (dd, *J* = 7.9, 1.1 Hz, 1H), 6.92 (td, *J* = 7.4, 1.1 Hz, 1H), 4.30 (dd, *J* = 10.2, 5.7 Hz, 1H), 3.46 (s, 3H), 3.12 (dd, *J* = 13.4, 5.8 Hz, 1H), 2.47 (dd, *J* = 13.6, 10.2 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 153.1, 143.4, 141.4, 133.5, 133.5, 129.3, 128.9, 128.5, 127.6, 127.5, 127.2, 122.9, 121.2, 116.9, 81.6, 71.5, 55.9, 36.6; IR (ATR): 1486, 1455, 1230, 1091, 1011, 816, 753 cm⁻¹; HRMS (ESI +) *m*/z calcd for C₂₂H₁₈O₂Na³⁵Cl₂ ([M + Na]⁺): 407.0576, found: 407.0573.

4-Methoxy-2-methyl-6-nitro-2-phenylchromane (3j). 5-Nitrosalicylaldehyde (83.6 mg, 0.50 mmol), α -methylstyrene (195 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). Yellow oil (127.2 mg, 85% yield, diastereomeric ratio 3:2). ¹H NMR (500 MHz, CDCl₃): (major) δ 8.38 (d, J = 2.8 Hz, 1H), 8.10 (m, 1H), 7.47–7.38 (m, 1H), 7.34–7.23 (m, 4H), 7.04 (dd, *I* = 10.7, 9.1 Hz, 1H), 4.57 (dd, J = 9.1, 5.7 Hz, 1H), 3.45 (s, 3H), 2.54 (ddd, *J* = 13.6, 5.7, 1.6 Hz, 1H), 2.20 (dd, *J* = 13.6, 9.1 Hz, 1H), 1.69 (s, 3H); (minor) δ 8.26 (dd, J = 2.8 Hz, 1H), 8.11 (m, 1H), 7.47– 7.38 (m, 1H), 7.34–7.23 (m, 4H), 7.04 (dd, J = 10.7, 9.1 Hz, 1H), 4.02 (dd, J = 10.6, 5.5 Hz, 1H), 3.48 (s, 3H), 2.90 (dd, J = 13.4, 5.5)Hz, 1H), 2.09 (dd, J = 13.4, 10.6 Hz, 1H), 1.74 (s, 3H); ${}^{13}C{}^{1}H{}$ NMR (126 MHz, CDCl₃): (mixture) δ 158.9, 158.6, 145.0, 143.6, 141.2, 141.1, 128.7, 128.3, 127.3, 124.9, 124.8, 124.8, 124.1, 124.0, 123.0, 117.7, 117.1, 81.2, 80.3, 70.9, 70.7, 56.2, 56.1, 37.8, 36.8, 31.2, 26.4; IR (ATR) (mixture): 1586, 1514, 1477, 1336, 1324, 1259, 1102, 1085, 749, 698 cm⁻¹; HRMS (ESI+) m/z calcd for C₁₇H₁₇NO₄Na $([M + Na]^{+})$: 322.1050, found: 322.1062.

2,2-Diheptyl-4-methoxy-6-nitrochromane (**3k**). 5-Nitrosalicylaldehyde (83.6 mg, 0.50 mmol), 2-heptyl-1-nonene (432 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). Yellow oil (30.4 mg, 15% yield). ¹H NMR (300 MHz, CDCl₃): δ 8.34 (dd, *J* = 3.0, 0.8 Hz, 1H), 8.05 (dd, *J* = 9.0, 3.0 Hz, 1H), 6.84 (d, *J* = 9.0 Hz, 1H), 4.41 (dd, *J* = 8.5, 5.8 Hz, 1H), 3.52 (s, 3H), 2.20 (dd, *J* = 13.6, 5.7 Hz, 1H), 1.88 (dd, *J* = 13.6, 8.7 Hz, 1H), 1.75–1.51 (m, 4H), 1.37–1.22 (m, 20H), 0.92–0.84 (m, 6H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 159.2, 140.9, 125.0, 123.0, 117.7, 81.9, 71.0, 56.5, 37.7, 36.3, 33.0, 31.8, 31.7, 29.9, 29.9, 29.2, 29.1, 23.3, 23.2, 22.6, 22.6, 14.1, 14.0; IR (ATR): 2926, 2855, 1586, 1518, 1479, 1334, 1260, 1085, 750 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₄H₄₀NO₄ ([M + H]⁺): 406.2952, found: 406.2948. 4-Methoxy-6-nitrospiro[chromane-2,9'-thioxanthene] (**3**). 5-Nitrosalicylaldehyde (36.5 mg, 0.22 mmol), 9-methylene-9H-thioxanthene (143.6 mg, 0.68 mmol), trimethyl orthoformate (50 μL, 0.46 mmol), and dry toluene (2.2 mL). White solid (95.4 mg, quant.). ¹H NMR (500 MHz, CDCl₃): δ 8.39 (dd, J = 2.9, 1.2 Hz, 1H), 8.28 (dd, J = 9.2, 2.9 Hz, 1H), 7.78 (dd, J = 8.0, 1.2 Hz, 1H), 7.55–7.53 (m, 1H), 7.50 (d, J = 7.4 Hz, 1H), 7.37–7.34 (m, 2H), 7.32–7.27 (m, 2H), 7.25–7.18 (m, 2H), 3.92 (dd, J = 10.6, 4.9 Hz, 1H), 3.29 (s, 3H), 3.19–3.15 (m, 1H), 1.76 (dd, J = 13.2, 10.3 Hz, 1H); $^{13}C{}^{1}$ H} NMR (126 MHz, CDCl₃): δ 159.4, 141.9, 138.2, 135.9, 129.8, 127.8, 127.6, 127.2, 126.9, 126.7, 125.5, 124.9, 124.7, 124.3, 123.8, 116.7, 81.2, 70.2, 56.3, 31.0; IR (ATR): 1586, 1434, 1335, 1255, 1240, 1087, 1020, 747 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₂H₁₈NO₄S ([M + H]⁺): 392.0951, found: 392.0969.

4-Methoxy-6-nitrospiro[chromane-2,5'-dibenzo[a,d][7]annulene] (**3m**). 5-Nitrosalicylaldehyde (83.2 mg, 0.50 mmol), 5methylene-5H-dibenzo[a,d][7] annulene (306.4 mg, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (188.9 mg, 98% yield). ¹H NMR (500 MHz, CDCl₃): δ 8.29–8.20 (m, 2H), 8.01 (d, *J* = 7.9 Hz, 1H), 7.49–7.46 (m, 1H), 7.43–7.39 (m, 4H), 7.35–7.26 (m, 3H), 7.13 (s, 2H), 3.65 (dd, *J* = 10.6, 4.9 Hz, 1H), 3.48–3.44 (m, 1H), 3.27 (s, 3H), 1.76 (dd, *J* = 13.5, 10.6 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 158.4, 141.7, 139.7, 137.4, 131.9, 131.7, 130.9, 130.0, 129.9, 129.2, 128.9, 127.2, 127.1, 125.2, 124.7, 124.3, 123.8, 123.3, 117.0, 82.8, 70.5, 56.0, 29.2; IR (ATR): 1473, 1376, 1262, 1034, 908, 739, 575 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₄H₂₀NO₄ ([M + H]⁺): 386.1387, found: 386.1377.

(25*,45*)-4-Methoxy-6-nitro-2-phenylchromane (**3***n*). 5-Nitrosalicylaldehyde (166.6 mg, 1.0 mmol), styrene (58 μL, 0.50 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL) for 24 h. Yellow solid (125.0 mg, 88% yield, cis/trans = 93/7). ¹H NMR (500 MHz, CDCl₃): δ 8.42 (d, *J* = 2.8 Hz, 1H), 8.06 (dd, *J* = 9.0, 2.7 Hz, 1H), 7.52–7.37 (m, 5H), 6.93 (d, *J* = 8.5 Hz, 1H), 5.25 (dd, *J* = 12.0, 1.9 Hz, 1H), 4.75 (dd, *J* = 10.7, 5.7 Hz, 1H), 3.55 (s, 3H), 2.65 (ddd, *J* = 13.1, 5.8, 2.2 Hz, 1H), 2.14–2.02 (m, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 159.8, 141.5, 139.3, 128.7, 128.6, 126.0, 124.8, 124.4, 123.9, 117.1, 78.0, 72.9, 56.3, 34.4; IR (ATR): 2929, 1584, 1512, 1342, 1253, 1080, 749 cm⁻¹; HRMS (ESI +) *m*/*z* calcd for C₁₆H₁₅NO₄ ([M + H]⁺): 286.1074, found: 286.1075.

6-Nitro-2,2-diphenyl-4-(2,2-diphenylvinyl)chromane (4a).³⁸ 5-Nitrosalicylaldehyde (82.3 mg, 0.49 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). Yellow solid (185.6 mg, 74% yield). ¹H NMR (300 MHz, CDCl₃): δ 8.09–8.03 (m, 2H), 7.43–7.23 (m, 15H), 7.16–7.03 (m, 6H), 6.08 (d, *J* = 9.4 Hz, 1H), 3.68–3.55 (m, 1H), 2.87 (dd, *J* = 14.3, 5.3 Hz, 1H), 2.35 (dd, *J* = 14.1, 12.6 Hz, 1H).

2,2-Diphenyl-4-(2,2-diphenylethenyl)-6-tosyloxychromane (**4b**). 2-Hydroxy-5-tosyloxybenzaldehyde (143.4 mg, 0.49 mmol), 1,1diphenylethylene (264 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). White solid (165.6 mg, 69% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.68–7.61 (m, 2H), 7.41–7.31 (m, 5H), 7.31–7.18 (m, 8H), 7.16–7.04 (m, 9H), 6.95 (d, *J* = 9.1 Hz, 1H), 6.89–6.79 (m, 1H), 6.64 (d, *J* = 2.8 Hz, 1H), 5.89 (d, *J* = 9.5 Hz, 1H), 3.49–3.37 (m, 1H), 2.75 (dd, *J* = 14.0, 5.5 Hz, 1H) 2.26–2.21 (m, 4H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 152.2, 145.4, 145.0, 144.8, 143.1, 142.2, 141.1, 139.4, 132.6, 129.5, 129.4, 129.2, 128.6, 128.4, 128.3, 128.2, 128.2, 127.5, 127.4, 127.3, 127.0, 126.2, 125.8, 125.6, 122.1, 121.8, 118.0, 81.9, 38.4, 34.0, 21.5; IR (ATR): 1483, 1370, 1175, 1092, 948, 832, 695 cm⁻¹; HRMS (ESI +) *m*/*z* calcd for C₄₂H₃₄O₄NaS ([M + Na]⁺): 657.2070, found: 657.2076.

4-(2,2-Diphenylethenyl)-6-methoxycarbonyl-2,2-diphenyl-chromane (4c). Methyl-3-formyl-4-hydroxybenzoate (89.0 mg, 0.49 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (231.2 mg, 90% yield). ¹H NMR (500 MHz, CDCl₃): *δ* 7.89–7.82 (m, 2H), 7.43–7.32 (m, 5H), 7.30–7.16 (m, 10H), 7.10–7.04 (m, 6H), 6.13 (d, J = 9.5 Hz, 1H), 3.84 (s, 3H), 3.59 (t, J = 12.9 Hz, 1H), 2.81 (dd, J = 13.9, 5.4 Hz, 1H), 2.37–2.28 (m, 1H); ${}^{13}C{}^{1}H{}$ NMR (126 MHz, CDCl₃): δ 166.8, 157.7, 145.2, 144.8, 142.2, 141.1, 139.5, 130.8, 129.7, 129.7, 129.3, 128.6, 128.3, 128.2, 127.4, 127.2, 127.1, 127.0, 126.0, 125.6, 124.8, 122.6, 117.2, 82.4, 51.7, 38.6, 33.8; IR (ATR): 1713, 1491, 1285, 1259, 763, 695 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{37}H_{31}O_3$ ([M + H]⁺): 523.2268, found: 523.2267.

6-Bromo-4-(2,2-diphenylethenyl)-2,2-diphenylchromane (**4d**).³⁸ 5-Bromosalicylaldehyde (99.7 mg, 0.50 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (218.4 mg, 81% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.41–7.33 (m, 5H), 7.30–7.17 (m, 12H), 7.12–7.04 (m, 5H), 6.94 (d, *J* = 8.8 Hz, 1H), 6.09 (d, *J* = 9.8 Hz, 1H), 3.58–3.50 (m, 1H), 2.77 (dd, *J* = 14.2, 5.4 Hz, 1H), 2.29 (dd, *J* = 14.0, 12.5 Hz, 1H).

2,2-Diphenyl-4-(2,2-diphenylethenyl)-7-tosyloxychromane (4e). 2-Hydroxy-4-tosyloxybenzaldehyde (145.3 mg, 0.50 mmol), 1,1diphenylethylene (264 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). White solid (250.3 mg, 79% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.78–7.70 (m, 2H), 7.42–7.18 (m, 17H), 7.14–7.05 (m, 3H), 7.05–6.99 (m, 3H), 6.62 (d, *J* = 2.5 Hz, 1H), 6.55 (dd, *J* = 8.4, 2.4 Hz, 1H), 6.04 (d, *J* = 9.3 Hz, 1H), 3.55–3.46 (m, 1H), 2.77 (dd, *J* = 13.9, 5.4 Hz, 1H), 2.46 (s, 3H), 2.27 (dd, *J* = 14.0, 12.5 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 154.1, 148.9, 145.3, 145.2, 144.5, 142.2, 141.2, 139.5, 132.6, 130.0, 129.7, 129.5, 129.3, 128.6, 128.6, 128.3, 128.2, 127.5, 127.5, 127.3, 127.1, 127.0, 126.2, 125.6, 123.9, 114.6, 111.2, 82.1, 38.6, 33.7, 21.7; IR (ATR): 1489, 1349, 1174, 1091, 963, 828, 820, 809, 695 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₄₂H₃₅O₄S ([M + H]⁺): 635.2251, found: 635.2271.

7-Bromo-4-(2,2-diphenylethenyl)-2,2-diphenylchromane (4f).^{6c} 4-Bromosalicylaldehyde (99.3 mg, 0.49 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (230.7 mg, 86% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.40–7.32 (m, 5H), 7.32–7.18 (m, 11H), 7.13–7.07 (m, 5H), 7.01–6.94 (m, 2H), 6.06 (d, *J* = 9.5 Hz, 1H), 3.49 (ddd, *J* = 12.4, 9.5, 5.5 Hz, 1H), 2.79 (dd, *J* = 14.0, 5.5 Hz, 1H), 2.29 (dd, *J* = 13.9, 12.3 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 154.4, 145.4, 144.5, 142.3, 141.2, 139.5, 130.1, 130.0, 129.3, 128.6, 128.4, 128.3, 128.2, 127.5, 127.4, 127.3, 127.1, 127.0, 126.2, 125.6, 124.0, 123.7, 120.6, 120.2, 82.1, 38.6, 33.7; IR (ATR): 1508, 1445, 1228, 1031, 759, 695 cm⁻¹; LRMS (EI+) *m*/*z* calcd for C₃₅H₂₈⁷⁹Br O ([M + H]⁺): 543.1318, found: 543.1.

2,3-Dihydro-1-(2,2-dipenylethenyl)-3,3-diphenyl-1H-naphto[2,1b]pyran (4g). 2-Hydroxy-1-naphthaldehyde (85.8 mg, 0.50 mmol), 1,1-diphenylethylene (264 μ L, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). White solid (220.6 mg, 86% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.94 (d, *J* = 8.5 Hz, 1H), 7.70 (d, *J* = 8.2 Hz, 1H), 7.66 (d, *J* = 8.8 Hz, 1H), 7.57–7.51 (m, 2H), 7.49–7.45 (m, 3H), 7.42 (d, *J* = 8.2 Hz, 2H), 7.33–7.10 (m, 13H), 7.08–7.04 (m, 3H), 6.07 (d, *J* = 9.1 Hz, 1H), 3.99–3.91 (m, 1H), 2.97 (dd, *J* = 14.2, 6.6 Hz, 1H), 2.56 (dd, *J* = 14.2, 10.1 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 151.6, 145.5, 142.6, 141.4, 140.7, 139.9, 134.0, 133.1, 129.7, 129.4, 128.8, 128.8, 128.4, 128.3, 128.2, 128.1, 127.4, 127.2, 127.1, 127.1, 126.9, 126.3, 125.9, 125.7, 124.3, 123.1, 119.7, 116.9, 81.1, 40.0, 32.5; IR (ATR): 1058, 1248, 1228, 1033, 821, 697 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₃₉H₃₁O ([M + H]⁺): 515.2369, found: 515.2345.

4-(2,2-Diphenylethenyl)-2,2-diphenylchromane (**4**h). Salicylaldehyde (48.3 μL, 0.50 mmol), 1,1-diphenylethylene (264 μL, 1.5 mmol), trimethyl orthoformate (109 μL, 1.0 mmol), and dry toluene (5.0 mL). White solid (192.0 mg, 83% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.43–7.33 (m, 5H), 7.31–7.20 (m, 10H), 7.19–7.03 (m, 8H), 6.86 (t, *J* = 7.4 Hz, 1H), 6.13 (d, *J* = 9.4 Hz, 1H), 3.61–3.52 (m, 1H), 2.80 (dd, *J* = 14.0, 5.5 Hz, 1H), 2.33 (dd, *J* = 13.9, 12.3 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 153.6, 146.0, 144.1, 142.8, 141.5, 139.7, 130.8, 129.4, 128.8, 128.5, 128.3, 128.2, 128.2, 127.8, 127.3, 127.2, 127.0, 126.9, 126.3, 125.7, 124.8, 120.6, 117.3, 81.5, 38.8, 34.0; IR (ATR): 1483, 1444, 4091, 1015, 759, 750, 698

cm⁻¹; HRMS (ESI+) m/z calcd for C₃₅H₂₉O ([M + H]⁺): 465.2213, found: 465.2198.

2,2-Bis(4-chlorophenyl)-4-(2,2-bis(4-chlorophenyl)ethenyl)chromane (**4i**).³⁸ Salicylaldehyde (48.3 μ L, 0.50 mmol), 1,1-bis(4chlorophenyl)ethylene (371.8 mg, 1.5 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL). Yellow solid (285.7 mg, 95% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.38 (d, *J* = 7.5 Hz, 2H), 7.30–7.23 (m, 6H), 7.20–6.98 (m, 11H), 6.89 (t, *J* = 7.4 Hz, 1H), 6.12 (d, *J* = 9.8 Hz, 1H), 3.45–3.38 (m, 1H), 2.61 (dd, *J* = 13.9, 5.4 Hz, 1H), 2.31–2.23 (m, 1H).

3,3-Diphenyl-3H-naphto[2,1-b]pyran (5g). 2-Hydroxy-1-naphthaldehyde (172.6 mg, 1.0 mmol), 1,1-diphenylethylene (87.8 μ L, 0.50 mmol), trimethyl orthoformate (109 μ L, 1.0 mmol), and dry toluene (5.0 mL) for 6 h. White solid (110.5 mg, 66% yield). ¹H NMR (500 MHz, CDCl₃): δ 7.95 (d, *J* = 8.5 Hz, 1H), 7.70 (d, *J* = 8.1 Hz, 1H), 7.65 (d, *J* = 8.7 Hz, 1H), 7.52–7.43 (m, 5H), 7.34–7.27 (m, 6H), 7.27–7.22 (m, 2H), 7.20 (d, *J* = 8.8 Hz, 1H), 6.25 (d, *J* = 9.7 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 150.5, 144.8, 129.8, 129.8, 129.3, 128.5, 128.1, 127.7, 127.5, 127.0, 126.6, 123.6, 121.3, 119.5, 118.3, 114.0, 82.5; IR (ATR): 1737, 1260, 1216, 1093, 1008, 802, 697 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₂₅H₁₉O ([M + H]⁺): 335.1430, found: 335.1439.

(25*,45*)-2,4-Dimethoxy-6-nitro-2-(4-nitrophenyl)chromane (**6a**). 5-Nitrosalicylaldehyde (334.6 mg, 2.0 mmol), 4'-nitroacetophenone (163.5 mg, 1.0 mmol), trimethyl orthoformate (438 μL, 4.0 mmol), and dry toluene (5.0 mL) at 40 °C for 24 h. Yellow solid (282.0 mg, 79% yield, cis/trans = 1/11). ¹H NMR (500 MHz, CDCl₃): δ 8.49–8.46 (m, 1H), 8.33 (d, *J* = 7.9 Hz, 2H), 8.18 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.82–7.78 (m, 2H), 7.13 (d, *J* = 9.1 Hz, 1H), 4.87 (dd, *J* = 10.9, 6.2 Hz, 1H), 3.55 (s, 3H), 3.10 (s, 3H), 2.77 (dd, *J* = 13.1, 6.2 Hz, 1H), 1.85 (dd, *J* = 13.2, 11.0 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 156.1, 148.3, 146.1, 142.7, 127.3, 125.2, 125.0, 124.0, 123.9, 117.6, 102.9, 70.6, 56.9, 50.9, 38.4; IR (ATR): 1509, 1344, 1086, 749 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₁₇H₁₆N₂O₇Na ([M + Na]⁺): 383.0850, found: 383.0867.

(25*,45*)-2-(4-Cyanophenyl)-2,4-dimethoxy-6-nitrochromane (**6b**). 5-Nitrosalicylaldehyde (334.8 mg, 2.0 mmol), 4'-cyanoacetophenone (144.2 mg, 1.0 mmol), trimethyl orthoformate (438 μL, 4.0 mmol), and dry toluene (5.0 mL) at 40 °C for 24 h. Yellow solid (325.0 mg, 96% yield, cis/trans = 1/8). ¹H NMR (500 MHz, CDCl₃): δ 8.46 (d, *J* = 2.8 Hz, 1H), 8.17 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.79–7.75 (m, 2H), 7.75–7.71 (m, 2H), 7.11 (d, *J* = 9.1 Hz, 1H), 4.86 (dd, *J* = 11.0, 6.3 Hz, 1H), 3.54 (s, 3H), 3.08 (s, 3H), 2.74 (dd, *J* = 13.2, 6.3 Hz, 1H), 1.82 (dd, *J* = 13.2, 11.0 Hz, 1H); $^{13}C{^{1}H}$ NMR (126 MHz, CDCl₃): δ 156.1, 144.3, 142.6, 132.6, 126.9, 125.2, 124.9, 123.8, 118.3, 117.5, 112.9, 102.9, 70.6, 56.8, 50.9, 38.4; IR (ATR): 3492, 2932, 2232, 1516, 1341, 1258, 1030, 839, 758 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₁₈H₁₆N₂O₃Na ([M + Na]⁺): 363.0951, found: 363.0961.

(25*,45*)-2-(4-Fluorophenyl)-2,4-dimethoxy-6-nitrochromane (**6c**). 5-Nitrosalicylaldehyde (332.9 mg, 2.0 mmol), 4'-fluoroacetophenone (121 μL, 1.0 mmol), trimethyl orthoformate (438 μL, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (295.5 mg, 89% yield, cis/trans = 1/13). ¹H NMR (500 MHz, CDCl₃): δ 8.45 (d, *J* = 2.8 Hz, 1H), 8.14 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.63–7.54 (m, 2H), 7.18– 7.08 (m, 3H), 4.86 (dd, *J* = 11.2, 6.2 Hz, 1H), 3.54 (s, 3H), 3.08 (s, 3H), 2.77 (dd, *J* = 13.1, 6.2 Hz, 1H), 1.83 (dd, *J* = 13.2, 11.0 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 162.8 (d, *J* = 248.9 Hz), 156.6, 142.3, 135.1 (d, *J* = 2.8 Hz), 127.9 (d, *J* = 8.3 Hz), 125.3, 124.7, 123.7, 117.5, 115.5 (d, *J* = 22.0 Hz), 103.3, 70.7, 56.6, 50.5, 38.7; IR (ATR): 1509, 1218, 1024, 842, 751 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₁₇H₁₆NO₅FNa ([M + Na]⁺): 356.0905, found: 356.0897.

 $(25^*,45^*)$ -2-(4-Chlorophenyl)-2,4-dimethoxy-6-nitrochromane (6d). 5-Nitrosalicylaldehyde (335.0 mg, 2.0 mmol), 4'-chloroacetophenone (123 μ L, 1.0 mmol), trimethyl orthoformate (438 μ L, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (352.0 mg, quant., cis/trans = 1/12). ¹H NMR (500 MHz, CDCl₃): δ 8.45 (dd, J = 2.8, 1.0 Hz, 1H), 8.20–8.12 (m, 1H), 7.56–7.50 (m, 2H), 7.47–7.40 (m, 2H), 7.10 (d, J = 8.8 Hz, 1H), 4.84 (dd, J = 11.0, 6.3 Hz, 1H), 3.54 (s, 3H), 3.07 (s, 3H), 2.75 (dd, J = 13.1, 6.2 Hz, 1H), 1.82 (dd, J = 13.2, 11.0 Hz, 1H); ${}^{13}C{}^{1}H$ NMR (126 MHz, CDCl₃): δ 156.5, 142.4, 137.8, 134.8, 128.8, 127.5, 125.3, 124.7, 123.7, 117.5, 103.2, 70.7, 56.7, 50.6, 38.5; IR (ATR): 1509, 1332, 1104, 1027, 892 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{17}H_{16}NO_5Na^{35}Cl$ ([M + Na]⁺): 372.0609, found: 372.0602.

(2S*,4S*)-2-(2,4-Difluorophenyl)-2,4-dimethoxy-6-nitrochromane (6e). 5-Nitrosalicylaldehyde (333.0 mg, 2.0 mmol), 2',4'difluoroacetophenone (126 μ L, 1.0 mmol), trimethyl orthoformate (438 µL, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (264.7 mg, 75% yield, cis/trans = 1/7). ¹H NMR (500 MHz, CDCl₃): δ 8.47-8.42 (m, 1H), 8.15 (dd, J = 8.8, 2.8 Hz, 1H), 7.72 (dt, J = 8.8, 6.3 Hz, 1H), 7.09 (d, J = 8.8 Hz, 1H), 6.97 (t, J = 8.2 Hz, 1H), 6.93-6.88 (m, 1H), 4.85 (dd, J = 11.0, 6.3 Hz, 1H), 3.56 (s, 3H), 3.13 (s, 3H), 3.05 (dd, *J* = 13.1, 6.2 Hz, 1H), 1.89 (dd, *J* = 13.1, 11.2 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 163.4 (dd, *J* = 252.0, 11.9 Hz), 160.0 (dd, J = 254.8, 11.9 Hz), 156.0, 142.4, 130.0 (dd, J = 9.2, 4.6 Hz), 125.4, 124.8, 123.8, 122.0 (dd, J = 11.0, 4.6 Hz), 117.5, 111.3 (dd, J = 21.1, 3.7 Hz), 105.0 (t, J = 26.1 Hz), 101.8 (d, J = 3.7 Hz),70.4, 56.8, 50.8, 36.2 (d, J = 2.8 Hz); IR (ATR): 1515, 1343, 1102, 851 cm⁻¹; HRMS (ESI+) m/z calcd for C₁₇H₁₅NO₅F₂Na ([M + Na]⁺): 374.0811, found: 374.0795.

(25*,45*)-2,4-Dimethoxy-6-nitro-2-phenylchromane (**6f**). 5-Nitrosalicylaldehyde (334.0 mg, 2.0 mmol), acetophenone (117 μL, 1.0 mmol), trimethyl orthoformate (438 μL, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (294.9 mg, 94% yield, cis/trans = 1/8). ¹H NMR (500 MHz, CDCl₃): δ 8.46 (dd, J = 2.7, 1.1 Hz, 1H), 8.15 (dd, J = 9.0, 2.7 Hz, 1H), 7.60–7.56 (m, 2H), 7.52–7.45 (m, 2H), 7.45–7.41 (m, 1H), 7.10 (d, J = 8.8 Hz, 1H), 4.86 (dd, J = 11.2, 6.2 Hz, 1H), 3.53 (s, 3H), 3.09 (s, 3H), 2.78 (dd, J = 13.2, 6.3 Hz, 1H), 1.85 (dd, J = 13.2, 11.4 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 156.9, 142.4, 139.2, 128.8, 128.7, 126.0, 125.4, 124.8, 123.8, 117.6, 103.7, 70.8, 56.7, 50.6, 38.7; IR (ATR): 1519, 1331, 1103, 1027, 893, 746 cm⁻¹; HRMS (ESI+) *m*/*z* calcd for C₁₇H₁₇NO₅Na ([M + Na]⁺): 338.0999, found: 338.1013.

(25*,45*)-6-Cyano-2,4-dimethoxy-2-phenylchromane (**6g**). 5-Cyanosalicylaldehyde (292.2 mg, 2.0 mmol), acetophenone (117 μ L, 1.0 mmol), trimethyl orthoformate (438 μ L, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (273.6 mg, 93% yield, cis/trans = 1/5.5). ¹H NMR (500 MHz, CDCl₃): δ 7.85 (d, *J* = 1.0 Hz, 1H), 7.62–7.56 (m, 2H), 7.52 (dd, *J* = 8.5, 1.9 Hz, 1H), 7.49–7.38 (m, 3H), 7.08 (d, *J* = 8.5 Hz, 1H),4.83 (dd, *J* = 11.2, 6.2 Hz, 1H), 3.50 (s, 3H), 3.08 (s, 3H), 2.75 (dd, *J* = 13.2, 6.3 Hz, 1H), 1.83 (dd, *J* = 13.1, 11.1 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 155.2, 139.4, 132.8, 131.9, 128.7, 128.6, 125.9, 125.8, 119.1, 117.9, 105.0, 103.3, 70.7, 56.5, 50.5, 38.7; IR (ATR): 2246, 1255, 1026, 701 cm⁻¹; HRMS (ESI +) *m*/*z* calcd for C₁₈H₁₈NO₃ ([M + H]⁺): 296.1281, found: 296.1286.

(25*,45*)-2,4-Dimethoxy-2-phenyl-6-tosyloxychromane (**6h**). 2-Hydroxy-5-tosyloxybenzaldehyde (290.7 mg, 1.0 mmol), acetophenone (58 μL, 0.50 mmol), trimethyl orthoformate (219 μL, 2.0 mmol), and dry toluene (2.5 mL). Yellow solid (187.6 mg, 85% yield, cis/trans = 1/11). ¹H NMR (500 MHz, CDCl₃): δ 7.81–7.74 (m, 2H), 7.61–7.55 (m, 2H), 7.45–7.40 (m, 2H), 7.39–7.36 (m, 1H), 7.33 (d, *J* = 8.51 Hz, 2H), 7.17–7.12 (m, 1H), 6.92–6.86 (m, 1H), 6.86–6.82 (m, 1H), 4.77 (dd, *J* = 11.0, 6.3 Hz, 1H), 3.35 (s, 3H), 3.04 (s, 3H), 2.63 (dd, *J* = 12.9, 6.3 Hz, 1H), 2.46 (s, 3H), 1.80 (dd, *J* = 13.1, 11.2 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 150.2, 145.1, 143.6, 140.0, 132.6, 129.7, 128.5, 128.5, 126.0, 125.3, 122.7, 121.0, 117.6, 102.6, 71.0, 55.8, 50.3, 38.5, 21.6; IR (ATR): 2970, 1371, 1176, 947, 838, 730 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₂₄H₂₄O₆NaS ([M + Na]⁺): 463.1186, found: 463.1202.

(25*,45*)-6-Bromo-2,4-dimethoxy-2-phenylchromane (**6i**). 5-Bromosalicylaldehyde (403.2 mg, 2.0 mmol), acetophenone (117 μ L, 1.0 mmol), trimethyl orthoformate (438 μ L, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (342.9 mg, 98% yield, cis/trans = 1/ 18). ¹H NMR (500 MHz, CDCl₃): δ 7.68–7.52 (m, 3H), 7.46–7.28 (m, 4H), 6.89 (d, *J* = 8.6 Hz, 1H), 4.82 (dd, *J* = 10.9, 6.3 Hz, 1H), 3.46 (s, 3H), 3.05 (s, 3H), 2.68 (dd, *J* = 13.5, 6.5 Hz, 1H), 1.82 (dd, *J* = 12.9, 11.2 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 150.7, 140.1, 131.7, 129.9, 128.5, 126.3, 126.0, 118.7, 113.9, 102.5, 71.2, 56.3, 50.3, 38.8; IR (ATR): 2937, 1483, 1237, 1027, 908, 700 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{17}H_{17}O_3Na^{79}Br$ ([M + N]⁺): 371.0253 found: 371.0269.

(25*,45*)-2,4-Dimethoxy-2-phenyl-7-tosyloxychromane (6j). 2-Hydroxy-4-tosyloxybenzaldehyde (574.1 mg, 2.0 mmol), acetophenone (117 μL, 1.0 mmol), trimethyl orthoformate (438 μL, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (312.3 mg, 71% yield, cis/trans = 1/11). ¹H NMR (500 MHz, CDCl₃): δ 7.74 (d, *J* = 8.6 Hz, 2H), 7.56 (d, *J* = 7.2 Hz, 2H), 7.48–7.33 (m, 4H), 7.30 (d, *J* = 8.0 Hz, 2H), 6.74–6.67 (m, 1H), 6.65–6.60 (m, 1H), 4.78 (dd, *J* = 10.9, 6.3 Hz, 1H), 3.44 (s, 3H), 3.01 (s, 3H), 2.68 (dd, *J* = 12.9, 6.0 Hz, 1H), 2.42 (s, 3H), 1.80 (dd, *J* = 13.2, 10.9 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 152.1, 149.6, 145.2, 139.8, 132.3, 129.7, 128.5, 128.4, 127.9, 125.9, 123.3, 115.2, 111.1, 102.8, 71.1, 56.2, 50.2, 38.9, 21.6; IR (ATR): 2939, 2360, 1373, 1091, 963, 825, 702 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₂₄H₂₄O₆NaS ([M + Na]⁺): 463.1186, found: 463.1195.

(25*,45*)-7-Bromo-2,4-dimethoxy-2-phenylchromane (**6**k). 4-Bromosalicylaldehyde (410.1 mg, 2.0 mmol), acetophenone (117 μL, 1.0 mmol), trimethyl orthoformate (438 μL, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (214.6 mg, 61% yield, cis/trans = 1/ 7). ¹H NMR (500 MHz, CDCl₃): δ 7.60–7.56 (m, 2H), 7.46–7.41 (m, 2H), 7.40–7.35 (m, 2H), 7.20 (d, *J* = 1.72 Hz, 1H), 7.15 (dd, *J* = 8.3, 2.0 Hz, 1H), 4.79 (dd, *J* = 11.5, 6.3 Hz, 1H), 3.46 (s, 3H), 3.07 (s, 3H), 2.69 (dd, *J* = 12.9, 6.0 Hz, 1H), 1.83 (dd, *J* = 12.9, 11.2 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 152.4, 140.0, 128.5, 128.5, 126.0, 124.6, 123.4, 121.7, 120.0, 102.8, 71.1, 56.1, 50.4, 38.9; IR (ATR): 3350, 2935, 1409, 1224, 991, 699 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₁₇H₁₇O₃Na⁷⁹Br ([M + Na]⁺): 371.0253, found: 371.0258.

(2R*,4S*)- and (2S*,4S*)-2,4-Dimethoxy-2-phenylchromane (61). Salicylaldehyde (244 μ L, 2.0 mmol), acetophenone (117 μ L, 1.0 mmol), trimethyl orthoformate (438 μ L, 4.0 mmol), and dry toluene (5.0 mL). Yellow solid (169.2 mg, 63% yield, cis/trans = 1/ 6.5). ¹H NMR (500 MHz, CDCl₃) (trans): δ 7.68-7.60 (m, 2H), 7.51 (d, I = 7.6 Hz, 1H), 7.47–7.41 (m, 2H), 7.41–7.35 (m, 1H), 7.27-7.22 (m, 1H), 7.09-7.00 (m, 2H), 4.87 (dd, J = 11.0, 6.3 Hz, 1H), 3.47 (s, 3H), 3.07 (s, 3H), 2.69 (dd, J = 13.1, 6.2 Hz, 1H), 1.88 (dd, I = 13.0, 11.0 Hz, 1H); (cis): δ 7.60–7.56 (m, 2H), 7.43–7.39 (m, 3H), 7.38-7.33 (m, 1H), 7.30-7.27 (m, 1H), 7.08-7.01 (m, 2H), 4.23 (dd, J = 5.7, 3.5 Hz, 1H), 3.54 (s, 3H), 3.11 (s, 3H), 2.63 $(dd, J = 13.7, 3.6 \text{ Hz}, 2\text{H}), 2.23 (dd, J = 14.7, 5.8 \text{ Hz}, 2\text{H}); {}^{13}\text{C}{}^{1}\text{H}$ NMR (126 MHz, CDCl₃) (trans): δ 151.6, 140.6, 128.8, 128.4, 128.3, 127.0, 126.1, 124.2, 121.4, 116.8, 102.3, 71.5, 56.0, 50.2, 39.2; (cis): δ 151.8, 140.9. 129.5, 129.5, 128.4, 128.2, 126.2, 123.0, 121.4, 117.4, 100.7, 71.8, 57.0, 50.4, 39.3; IR (ATR) (trans): 2938, 1449, 1213, 1092, 1025, 907, 751 cm⁻¹; (cis): 1450, 1228, 1147, 1095, 1016, 808, 755, 565 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{17}H_{18}O_3Na$ ([M + Na]⁺) (trans): 293.1148, found: 293.1159; (cis): 293.1148, found: 293.1158

Transformation of Chromane 3a. Transformation of 4-Methoxy-6-nitro-2,2-diphenylchromane (3a) into 6-Nitro-2,2-diphenyl-4-tosylamidechromane (7a). 4-Methoxy-6-nitro-2,2-diphenylethylene (3a, 89.3 mg, 0.25 mmol), p-toluenesulfonamide (429.1 mg, 2.5 mmol), and FeCl₃ (20 mol %) were dissolved in dry dichloroethane (3.0 mL) under an atmosphere of nitrogen. After stirring for 3 h at 60 °C, the reaction mixture was neutralized with H2O. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5.0 mL \times 3). The combined organic phases were washed with brine, dried over Na2SO4, and filtered. The filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 5/1, v/v) to afford 6-nitro-2,2-diphenyl-4-tosylamidechromane (7a, 111.6 mg, 90% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.03 (dd, J = 9.1, 2.5 Hz, 1H), 7.94-7.90 (m, 1H), 7.77 (d, J = 8.2 Hz, 1H)2H), 7.35 (d, J = 8.2 Hz, 2H), 7.34-7.23 (m, 10H), 7.09 (d, J = 9.1 Hz, 1H), 5.19 (s, 1H), 4.34 (td, J = 10.3, 5.5 Hz, 1H), 3.06 (dd, J = 13.7, 5.5 Hz, 1H), 2.50–2.41 (m, 4H); ¹³C{¹H} NMR (126 MHz, $CDCl_3$): δ 159.0, 144.3, 143.2, 141.5, 141.2, 136.9, 130.0, 128.9, 128.4, 128.0, 128.0, 127.1, 125.7, 125.6, 125.1, 124.1, 123.0, 117.9,

84.2, 46.8, 38.9, 21.5; IR (ATR): 3251, 1513, 1316, 1158, 667, 556 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{28}H_{24}N_2O_5NaS$ ([M + Na]⁺): 523.1298, found: 523.1318.

Transformation of 4-Methoxy-6-nitro-2,2-diphenylchromane (3a) into 4-Allyl-6-nitro-2,2-diphenylchromane (8a). 4-Methoxy-6nitro-2,2-diphenylethylene (3a, 38.1 mg, 0.11 mmol), allyltrimethylsilane (159 μ L, 1.0 mmol), and FeCl₃ (10 mol %) were dissolved in CH_2Cl_2 (1.0 mL). After stirring at reflux for 7 h, the reaction mixture was quenched with H₂O. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5.0 mL \times 3). The combined organic layer was washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo. The resulting residue was purified by preparative TLC on silica gel (hexane) to afford 4-allyl-6-nitro-2,2-diphenylchromane (8a, 27.8 mg, 71% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.14 (dd, J = 2.7, 1.1 Hz, 1H), 8.07 (ddd, J = 8.8, 2.8, 0.6 Hz, 1H), 7.45-7.40 (m, 2H), 7.40-7.27 (m, 7H), 7.25-7.21 (m, 1H), 7.15 (d, J = 9.1 Hz, 1H), 5.84-5.74 (m, 1H), 5.21-5.13 (m, 2H), 2.99 (dd, J = 14.2, 5.4 Hz, 1H), 2.89–2.76 (m, 2H), 2.41–2.30 (m, 1H), 2.18 (dd, J = 14.2, 12.0 Hz, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 159.7, 144.9, 142.4, 141.4, 134.6, 128.7, 128.4, 127.7, 127.6, 126.1, 125.9, 125.7, 123.8, 123.6, 118.4, 118.0, 83.6, 37.9, 37.5, 31.2; IR (ATR): 2925, 1577, 1506, 1250, 1095, 1009, 748, 699 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{24}H_{21}NO_3Na$ ([M + Na]⁺): 394.1414, found: 394.1426.

Transformation of 4-Methoxy-6-nitro-2,2-diphenylchromane (3a) to 6-Amino-4-methoxy-2,2-diphenylchromane (9a). To 4-Methoxy-6-nitro-2,2-diphenylethylene (3a, 91.1 mg, 0.25 mmol) in EtOAc (2.5 mL), palladium on charcoal (10%, 14.9 mg) was added. After being stirred under hydrogen for 4 h, the reaction mixture was filtered. The filtrate was concentrated in vacuo to afford 6-amino-4methoxy-2,2-diphenylchromane (9a, 86.1 mg, quant.) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 7.45-7.40 (m, 4H), 7.32-7.18 (m, 6H), 6.87 (d, *I* = 8.8 Hz, 1H), 6.66 (d, *I* = 2.8 Hz, 1H), 6.57 (dd, *I* = 8.5, 3.2 Hz, 1H), 4.26 (dd, J = 10.4, 5.7 Hz, 1H), 3.45 (s, 3H), 3.20 (dd, J = 13.2, 6.0 Hz, 1H), 3.06 (s, 2H), 2.46 (dd, J = 13.2, 10.7 Hz, 1H); ${}^{13}C{}^{1}H$ NMR (126 MHz, CDCl₃): δ 146.7, 145.7, 143.1, 139.8, 128.4, 128.2, 127.3, 127.1, 126.3, 125.8, 123.5, 117.6, 116.9, 113.5, 82.1, 71.9, 55.6, 36.8; IR (ATR): 3356, 2818, 1493, 1216, 1089, 1018, 797, 735, 698 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{22}H_{22}NO_2$ ([M + H]⁺): 332.1645, found: 332.1656.

Transformation of 4-Methoxy-6-nitro-2,2-diphenylchromane (3a) to 3-Bromo-4-methoxy-6-nitro-2,2-diphenyl-2H-chromene (10a). A mixture of 4-methoxy-6-nitro-2,2-diphenylethylene (3a, 91.4 mg, 0.25 mmol) and NBS (136.0 mg, 0.76 mmol) was stirred at reflux for 24 h in CCl_4 (5.0 mL) under an atmosphere of nitrogen. After that, the reaction mixture was quenched with H₂O. The organic layer was separated, and the aqueous layer was extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane) to afford 3-bromo-4-methoxy-6-nitro-2,2diphenyl-2H-chromene (10a, 83.4 mg, 75% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 8.20 (d, J = 2.8 Hz, 1H), 8.06 (dd, J = 8.8, 2.8 Hz, 1H), 7.43–7.38 (m, 4H), 7.37–7.32 (m, 6H), 6.99 (d, J = 8.8 Hz, 1H), 3.91 (s, 3H); ${}^{13}C{}^{1}H$ NMR (126 MHz, CDCl₃): δ 157.9, 149.7, 142.6, 141.4, 128.7, 128.6, 127.9, 126.0, 120.1, 118.3, 117.7, 111.2, 89.6, 60.1; IR (ATR): 2962, 1519, 1341, 1260, 1069, 967, 907, 800, 751, 695 cm⁻¹; HRMS (ESI+) m/z calcd for $C_{22}H_{17}NO_4^{79}Br$ ([M + H]⁺): 438.0336, found: 438.0344.

Synthesis of 11. 5-Chlorosalicylaldehyde (155.6 mg, 0.99 mmol), *p*-chlorostyrene (64 μ L, 0.5 mmol), and trimethyl orthoformate (109 μ L, 1.0 mmol) were dissolved in dry toluene (5.0 mL) under an atmosphere of nitrogen before trifluoromethanesulfonic acid (20 mol %) was added. After stirring at room temperature for 24 h, the reaction mixture was neutralized with 5% aq NaHCO₃. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (5.0 mL × 3). The combined organic phases were washed with brine, dried over MgSO₄, and filtered before the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane/chloroform = 3/1, v/v) to afford ($2S^*,4S^*$)-6-chloro-2-(4-chlorophenyl)-4-methoxychromane

(11, 146.9 mg, 95% yield, cis/trans = 80/20) as a white solid. ¹H NMR (500 MHz, CDCl₃): δ 7.45 (dd, J = 2.5, 1.0 Hz, 1H), 7.38 (s, 4H), 7.13 (dd, J = 8.7, 2.7 Hz, 1H), 6.80 (d, J = 8.5 Hz, 1H), 5.10 (dd, J = 12.0, 1.9 Hz, 1H), 4.71 (dd, J = 10.7, 6.0 Hz, 1H), 3.49 (s, 3H), 2.51 (ddd, J = 13.2, 6.1, 1.9 Hz, 1H), 2.07–1.97 (m, 1H); ¹³C{¹H} NMR (126 MHz, CDCl₃): δ 153.1, 138.9, 134.1, 129.0, 128.8, 127.4, 127.2, 126.0, 124.9, 118.0, 76.4, 73.3 56.1, 34.9; IR (ATR): 2962, 1477, 1248, 1092, 814 cm⁻¹; HRMS (ESI+) *m/z* calcd for C₁₅H₁₁O³⁵Cl₂ ([M – OMe]⁺): 277.0182, found: 277.0179.

Synthesis of BW683C. $(2S^*, 4S^*)$ -6-Chloro-2-(4-chlorophenyl)-4-methoxychromane (11, 74.3 mg, 0.24 mmol), triethylsilane (60 μ L, 0.375 mmol), and FeCl₃ (10 mol %) were dissolved in dichloroethane (3.0 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with H₂O. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layer was washed with brine, dried over MgSO₄, filtered, and the filtrate was concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 30/1, v/v) to afford 6-chloro-2-(4-chlorophenyl)chromane (BW683C, 60.1 mg, 90% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ 7.37–7.32 (m, 4H), 7.09–7.05 (m, 2H), 6.82 (d, *J* = 8.4 Hz, 1H), 5.02 (dd, *J* = 10.0, 2.6 Hz, 1H), 2.95 (ddd, *J* = 16.8, 11.0, 6.0 Hz, 1H), 2.78–2.73 (m, 1H), 2.21–2.15 (m, 1H), 2.02 (dtd, *J* = 13.8, 10.6, 5.2 Hz, 1H).²¹

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.9b02036.

Crystallographic data for compound *cis*-6a (CIF)

Crystallographic data for compound trans-6a (CIF)

Crystallographic data for compound *cis*-3n (CIF)

NMR spectra of new compounds, X-ray crystallographic data of chromanes (*cis*-**3n** and **6a**); characterization of **3n**; computational data (PDF)

AUTHOR INFORMATION

Corresponding Authors

*E-mail: hoshino-yujiro-hy@ynu.ac.jp (Y.H.). *E-mail: honda-kiyoshi-rb@ynu.ac.jp (K.H.).

ORCID [©]

Kenta Tanaka: 0000-0001-8253-3561 Yujiro Hoshino: 0000-0002-8373-8013

Notes

The authors declare no competing financial interest.

REFERENCES

(1) (a) Hu, X.; Wu, J.-W.; Wang, M.; Yu, M.-H.; Zhao, Q.-S.; Wang, H.-Y.; Hou, A.-J. 2-Arylbenzofuran, Flavonoid, and Tyrosinase Inhibitory Constituents of *Morus yunnanensis*. J. Nat. Prod. 2012, 75, 82–87. (b) Wong, I. L. K.; Wang, B.-C.; Yuan, J.; Duan, L.-X.; Liu, Z.; Liu, T.; Li, X.-M.; Hu, X.; Zang, X.-Y.; Jiang, T.; Wan, S.-B.; Chow, L. M. C. Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives. J. Med. Chem. 2015, 58, 4529–4549.

(2) (a) Ramulu, B. V.; Mahendar, L.; Krishna, J.; Reddy, A. G. K.; Suchand, B.; Satyanarayana, G. Transition Metals Catalyzed C-C and C-O Bonds Formation: Facile Synthesis of Flavans and Benzoxepines. *Tetrahedron* 2013, 69, 8305–8315. (b) Rana, N.; Niharika, P.; Kishore, D. R.; Satyanarayana, G. One-Pot Heck and Reduction: Application Towards Efficient Synthesis of Flavans Promoted by Lewis Acid. *ChemistrySelect* 2017, 2, 10809–10813. (c) Shang, X.; Zhou, X.; Zhang, W.; Wan, C.; Chen, J. Tosylhydrazine Mediated Conjugate Reduction and Sequential Reductive Coupling Cyclization: Synthesis of 2-Arylchromans. *Tetrahedron* **2015**, *71*, 8187–8193.

(3) (a) Bauer, D. J.; Selway, J. W. T.; et al. 4',6-Dichloroflavan (BW683C), A New Anti-Rhinovims Compound. Nature 1981, 292, 369-373. (b) Gadwood, R. C.; Kamdar, B. V.; Dubray, L. A. C.; Wolfe, M. L.; Smith, M. P.; Watt, W.; Mizsak, S. A.; Groppi, V. E. Synthesis and Biological Activity of Spirocyclic Benzopyran Imidazolone Potassium Channel Openers. J. Med. Chem. 1993, 36, 1480-1487. (c) Chiou, W.-F.; Li, S.-Y.; Ho, L.-K.; Hsien, M.-L.; Don, M.-J. Synthesis and Vasorelaxant Activity of 4-(Cyclicamido)-2Hnaphtho[1,2-b]pyrans. Eur. J. Med. Chem. 2002, 37, 69-75. (d) Bergmann, R.; Gericke, R. Synthesis and Antihypertensive Activity of 4-(1,2-Dihydro-2-oxo-l-pyridyl)-2H-l-benzopyrands Related Compounds, New Potassium Channel Activators. J. Med. Chem. 1990, 33, 492-504. (e) Genovese, D.; Conti, C.; Tomao, P.; Desideri, N.; Stein, M. L.; Catone, S.; Fiore, L. Effect of Chloro-, Cyano-, and Amidino-Substituted Flavanoids on Enterovirus Infection In Vitro. Antiviral Res. 1995, 27, 123-136. (f) Conti, C.; Desideria, C. N.; Orsil, N.; Sestiliz, I.; Stein, M. L. Synthesis and Antirhinovirus Activity of Cyano and Amidino Substituted Flavanoids. Eur. J. Med. Chem. 1990, 25, 725-730. (g) Alejo-Armijo, A.; Glibota, N.; Frías, M. P.; Altarejos, J.; Gálvez, A.; Salido, S.; Ortega-Morente, E. Synthesis and Evaluation of Antimicrobial and Antibiofilm Properties of A-Type Procyanidin Analogues against Resistant Bacteria in Food. J. Agric. Food Chem. 2018, 66, 2151-2158. (h) Mannhold, R. KATP Channel Openers: Structure-Activity Relationships and Therapeutic Potential. Med. Res. Rev. 2004, 24, 213-266. (i) Sebille, S.; Gall, D.; de Tullio, P.; Florence, X.; Lebrun, P.; Pirotte, B. Design, Synthesis, and Pharmacological Evaluation of R/S-3,4-Dihydro-2,2-dimethyl-6-halo-4-(Phenylaminocarbonylamino)-2H-1-benzopyrans: Toward Tissue-Selective Pancreatic β -Cell K_{ATP} Channel Openers Structurally Related to (±)-Cromakalim. J. Med. Chem. 2006, 49, 4690-4697.

(4) (a) Ma, R.; Xu, S.; Tang, X.; Wu, G.; He, Z. Phosphine-Mediated Diverse Reactivity of γ -Substituted Allenoates with Aldehydes: Syntheses of Highly Functionalized Chromans and (E,E)-1,3-Dienes. Tetrahedron 2011, 67, 1053-1061. (b) Fazeli, A.; Pflasterer, D.; Rudolph, M.; Hashmi, A. S. K. An Easy Access to Chromanes via the Gold-Catalyzed Hydroarylation of Allenes. J. Organomet. Chem. 2015, 795, 68-70. (c) Parmar, N. J.; Pansuriya, B. R.; Labana, B. M.; Kant, R.; Gupta, V. K. A Convenient 1,3-Dipolar Cycloaddition-Reduction Synthetic Sequence from 2-Allyloxy-5nitrosalicylaldehyde to Aminobenzopyran-Annulated Heterocycles. RSC Adv. 2013, 3, 17527-17539. (d) Hryniewicka, A.; Suchodolski, S.; Wojtkielewicz, A.; Morzycki, J. W.; Witkowski, S. New Metathesis Catalyst Bearing Chromanyl Moieties at the N-Heterocyclic Carbene Ligand. Beilstein J. Org. Chem. 2015, 11, 2795-2804. (e) Inami, K.; Suzuki, M.; Shimizu, A.; Furukawa, M.; Morita, M.; Mochizuki, M. Substituent Effect on the Radical Scavenging Activity of 6-Chromanol Derivatives. RSC Adv. 2014, 4, 43882-43889. (f) Sebille, S.; Tullio, P.; Becker, B.; Antoine, M.-H.; Boverie, S.; Pirotte, B.; Lebrun, P. 4,6-Disubstituted 2,2-Dimethylchromans Structurally Related to the K_{ATP} Channel Opener Cromakalim: Design, Synthesis, and Effect on Insulin Release and Vascular Tone. J. Med. Chem. 2005, 48, 614-621. (5) (a) Nakamura, S.; Uchiyama, M.; Ohwada, T. 4H-1,2-Benzoxazines with Electron-Withdrawing Substituents on the Benzene Ring: Synthesis and Application as Potent Intermediates for Oxygen-Functionalized Aromatic Compounds. J. Am. Chem. Soc. 2003, 125, 5282-5283. (b) Sugimoto, H.; Nakamura, S.; Ohwada, T. Retro-Diels-Alder Reaction of 4H-1,2-Benzoxazines to Generate o-Quinone Methides: Involvement of Highly Polarized Transition States. J. Org. Chem. 2007, 72, 10088-10095. (c) Sugimoto, H.; Nakamura, S.; Ohwada, T. Generation and Application of o-Quinone Methides Bearing Various Substituents on the Benzene Ring. Adv. Synth. Catal. 2007, 349, 669-679.

(6) (a) Tanaka, K.; Kishimoto, M.; Ohtsuka, N.; Iwama, Y.; Wada, H.; Hoshino, Y.; Honda, K. Highly Selective One-Pot Synthesis of Polysubstituted Isoflavanes using Styryl Ethers and Electron-Withdrawing *ortho*-Quinone Methides Generated In Situ. *Synlett* **2019**, *30*, 189–192. (b) Tanaka, K.; Hoshino, Y.; Honda, K. Development of

Regioselective Inverse-Electron-Demand [4+2] Cycloaddition with Electron-Rich Arylalkynes for Access to Multi-Substituted Condensed Oxapolycyclic Compounds. J. Synth. Org. Chem., Jpn. 2018, 76, 1341-1351. (c) Tanaka, K.; Kishimoto, M.; Hoshino, Y.; Honda, K. Temperature-Controlled Divergent Synthesis of 4-Alkoxy- or 4-Alkenylchromanes via Inverse Electron-Demand Cycloaddition with in situ Generated ortho-Quinone Methides. Tetrahedron Lett. 2018, 59, 1841-1845. (d) Tanaka, K.; Sukekawa, M.; Hoshino, Y.; Honda, K. The Ring-Contraction Reaction of Electron-Deficient 3-Silylchromene to 2-Benzylbenzofuran under Mildly Basic Conditions. Chem. Lett. 2018, 47, 440-443. (e) Tanaka, K.; Sukekawa, M.; Kishimoto, M.; Hoshino, Y.; Honda, K. CsF-Promoted Desilylation and Ring-Contraction Reaction of Electron-Deficient 3-Silyl-2H-Chromenes to 2-Benzylbenzofurans. Heterocycles 2019, 99, 145-170. (f) Tanaka, K.; Kishimoto, M.; Sukekawa, M.; Hoshino, Y.; Honda, K. Green-lightdriven thioxanthylium-based organophotoredox catalysts: Organophotoredox promoted radical cation Diels-Alder reaction. Tetrahedron Lett. 2018, 59, 3361-3364. (g) Tanaka, K.; Omata, D.; Asada, Y.; Hoshino, Y.; Honda, K. Organophotoredox-catalyzed intermolecular oxa-[4+2] cycloaddition reactions. J. Org. Chem. 2019, 84, 10669-10678.

(7) (a) Tanaka, K.; Sukekawa, M.; Shigematsu, Y.; Hoshino, Y.; Honda, K. Highly Regioselective Synthesis of 2,3-Disubstituted 2H-1-Benzopyrans: Brønsted Acid Catalyzed [4+2] Cycloaddition Reaction with a Variety of Arylalkynes via ortho-Quinone Methides. Tetrahedron 2017, 73, 6456-6464. (b) Tanaka, K.; Hoshino, Y.; Honda, K. A Direct Synthesis of 2,2-Disubstituted 3-Silylchromenes by [4+2] Cycloaddition of in situ Generated o-Quinonemethides with Electron-Rich Alkynes. Heterocycles 2017, 95, 474-486. (c) Tanaka, K.; Shigematsu, Y.; Sukekawa, M.; Hoshino, Y.; Honda, K. Regioselective One-Pot Synthesis of 2,3-Diaryl-2H-1-benzopyrans via Brønsted Acid-Catalyzed [4+2] Cycloaddition of Salicylaldehydes with Diarylacetylenes. Tetrahedron Lett. 2016, 57, 5914-5918. (d) Tanaka, K.; Hoshino, Y.; Honda, K. A Novel Synthesis of Polysubstituted Chromenes from Various Salicylaldehydes and Alkynes under Mild Conditions. Tetrahedron Lett. 2016, 57, 2448-2450.

(8) Typical Brønsted acids have been used to generate *o*-QMs from *o*-hydroxybenzyl alcohols for the [4+2] cycloadditions; for details, see: (a) Shen, Y.-B.; Li, S.-S.; Liang, W.; An, X.-D.; Liu, Q.; Liu, X.; Xiao, J. Organocatalytic Dearomative [4 + 2] Cycloadditions of Biomass-Derived 2,5-Dimethylfuran with ortho-Quinone Methides: Access to Multisubstituted Chromanes. *Org. Lett.* **2018**, *20*, 6069–6073. (b) Green, J. C.; Brown, E. R.; Pettus, T. R. R. Intramolecular Condensation via an *o*-Quinone Methide: Total Synthesis of (\pm) -Heliol. *Org. Lett.* **2012**, *14*, 2929–2931.

(9) Yadav, J. Š.; Reddy, B. V. S.; Parisse, C.; Carvalho, P.; Rao, T. P. A Facile Synthesis of Indeno[1,2-*b*]chromanes Catalyzed by Scandium Triflate. *Tetrahedron Lett.* **2002**, *43*, 2999–3002.

(10) (a) Nicolaou, K. C.; Pfefferkorn, J. A.; Barluenga, S.; Mitchell, H. J.; Roecker, A. J.; Cao, G.-Q. Natural Product-like Combinatorial Libraries Based on Privileged Structures. 3. The "Libraries from Libraries" Principle for Diversity Enhancement of Benzopyran Libraries. J. Am. Chem. Soc. 2000, 122, 9968–9976. (b) Bharate, S. B.; Singh, I. P. A Two-step Biomimetic Synthesis of Antimalarial Robustadials A and B. Tetrahedron Lett. 2006, 47, 7021–7024.

(11) (a) Hobley, J.; Malatesta, V.; Millini, R.; Giroldini, W.; Wis, L.; Goto, M.; Kishimoto, M.; Fukumura, H. Photochromism of Chromene Crystals; A New Property of Old Chromenes. *Chem Commun.* **2000**, 1339–1340.

(12) (a) Alberti, A.; Teral, Y.; Roubaud, G.; Faure, R.; Campredon, M. On the Photochromic Activity of Some Diphenyl-3*H*-naphtho-[2,1-*b*]pyran Derivatives: Synthesis, NMR Characterisation and Spectrokinetic Studies. *Dyes Pigm.* **2009**, *81*, 85–90. (b) Lee, Y. R.; Kim, Y. M. A Novel Method for the Synthesis of Substituted Benzochromenes by Ethylenediamine Diacetate-Catalyzed Cyclizations of Naphthalenols to α , β -Unsaturated Aldehydes. Concise Synthesis of the Natural Products Lapachenole, Dihydrolapachenole, and Mollugin. *Helv. Chim. Acta* **2007**, *90*, 2401–2413. (c) Pozzo, J.- L.; Samat, A.; Guglielmetti, R.; Aubard, J. Synthesis and Photochromic Behaviour of Naphthopyrans, Pyranoquinolines, Pyranoquinazolines and Pyranoquinoxalines. *Helv. Chim. Acta* **1997**, *80*, 725– 738.

(13) Jones, R. M.; Selenski, C.; Pettus, T. R. R. Diastereoselective Syntheses of Chroman Spiroketals via [4 + 2] Cycloaddition of Enol Ethers and o-Quinone Methides. J. Org. Chem. 2002, 67, 6911–6915. (14) Selenski, C.; Pettus, T. R. R. Enantioselective [4 + 2] Cycloadditions of o-Quinone Methides: Total Synthesis of (+)-Mimosifoliol and Formal Synthesis of (+)-Tolterodine. J. Org. Chem. 2004, 69, 9196–9203.

(15) Byrne, P. A.; Kobayashi, S.; Würthwein, E.-U.; Ammer, J.; Mayer, H. Why Are Vinyl Cations Sluggish Electrophiles? J. Am. Chem. Soc. 2017, 139, 1499–1511.

(16) (a) Lee, J. J.; Pollock, G. R.; Mitchell, D.; Kasuga, L.; Kraus, G. A. Upgrading Malic Acid to Bio-Based Benzoates via a Diels-Alder-Initiated Sequence with the Methyl Coumalate Platform. *RSC Adv.* **2014**, *4*, 45657–45664. (b) Lee, J. J.; Kraus, G. A. Divergent Diels-Alder Methodology from Methyl Coumalate Toward Functionalized Aromatics. *Tetrahedron Lett.* **2013**, *54*, 2366–2368.

(17) The Yb(OTf)₃-catalyzed cycloaddition of 4'-bromoacetophenone with salicylaldehydes has already been reported; for details, see: Yadav, J. S.; Reddy, B. V. S.; Aruna, M.; Venugopal, C.; Ramalingam, T.; Kumar, S. K.; Kunwar, A. C. Metal Triflates Catalyzed Efficient Synthesis of 3,4-Dihydro-2*H*-1-benzopyrans. *J. Chem. Soc., Perkin Trans. 1* 2002, 165–171.

(18) (a) The details of the X-ray crystal structure analysis can be found in the Supporting Information. (b) Farrugia, L. J. WinGX and ORTEP for Windows: An Update. *J. Appl. Crystallogr.* **2012**, *45*, 849–854.

(19) Sidana, J.; Rohilla, R. K.; Roy, N.; Barrow, R. A.; Foley, W. J.; Singh, I. P. Antibacterial Sideroxylonals and Loxophlebal A from Eucalyptus Loxophleba Foliage. *Fitoterapia* **2010**, *81*, 878–883.

(20) (a) Yi, E.-Y.; Park, S.-Y.; Song, H. S.; Son, M. J.; Yi, K.-Y.; Yoo, S.-E.; Kim, Y.-J. KR-31831, A New Synthetic Anti-Ischemic Agent, Inhibits In Vivo and In Vitro Angiogenesis. *Exp. Mol. Med.* **2006**, *38*, 502–508. (b) Casano, G.; Dumètre, A.; Pannecouque, C.; Hutter, S.; Azas, N.; Robin, M. Anti-HIV and Antiplasmodial Activity of Original Flavonoid Derivatives. *Bioorg. Med. Chem.* **2010**, *18*, 6012–6023.

(21) (a) Böttcher, C.; Zeyat, G.; Ahmed, S. A.; Irran, E.; Cordes, T.; Elsner, C.; Zinth, W.; Rueck-Braun, K. Synthesis of Novel Photochromic Pyrans via Palladium-Mediated Reactions. *Beilstein J. Org. Chem.* **2009**, *5*, No. 25. (b) Koo, J. Y.; Oh, S.; Cho, S.-R.; Koh, M.; Oh, W.-K.; Choi, H.-S.; Park, S. B. Total Synthesis of Eryvarin H and Its Derivatives and Their Biological Activity as ERRγ Inverse Agonist. *Org. Biomol. Chem.* **2013**, *11*, 5782–5786. (c) Sastry, M. N. V.; Claessens, S.; Habonimana, P.; Kimpe, N. D. Synthesis of the Natural Products 3-Hydroxymollugin and 3-Methoxymollugin. *J. Org. Chem.* **2010**, *75*, 2274–2280. (d) Böhmdorfer, S.; Kloser, E.; Patel, A.; Gille, L.; Mereiter, K.; Rosenau, T. Novel Tocopherol Derivatives. Part 32: On the Bromination of Pyrano[3,2-f]chromenes Related to *γ*-Tocopherol. *Tetrahedron* **2011**, *67*, 6181–6185.

(22) (a) Mutoh, K.; Kobayashi, Y.; Abe, J. Efficient Coloration and Decoloration Reactions of Fast Photochromic 3*H*-Naphthopyrans in PMMA-*b*-PBA Block Copolymer. *Dyes Pigm.* 2017, *137*, 307–311.
(b) Arai, K.; Kobayashi, Y.; Abe, J. Rational Molecular Designs for Drastic Acceleration of the Color-Fading Speed of Photochromic Naphthopyrans. *Chem. Commun.* 2015, *51*, 3057–3060.

(23) (a) Orr, R. K.; Campeau, L.-C.; Chobanian, H. R.; McCabe Dunn, J. M.; Pio, B.; Plummer, C. W.; Nolting, A.; Ruck, R. T. A Modular Synthesis of 2-Alkyl- and 2-Arylchromans via a Three-Step Sequence. *Synthesis* **2017**, *49*, 657–666. (b) Jin, H. J.; Kim, J. H.; Kang, E. J. Regioselective Domino Synthesis of 2-Alkylflavans via Hidden Brønsted Acid Catalysis. *Synthesis* **2017**, *49*, 3137–3144.

(24) (a) Inoue, T.; Inoue, S.; Sato, K. A New Generation of *o*-Quinone Methides from *o*-(1-(Alkylthio)alkyl)phenols under Mild Conditions. *Chem. Lett.* **1989**, *18*, 653–656. (b) Marsini, M. A.; Huang, Y.; Lindsey, C. C.; Wu, K.-L.; Pettus, T. R. R. Rapid Syntheses

of Benzopyrans from *o*-OBOC Salicylaldehydes and Salicyl Alcohols: A Three-Component Reaction. Org. Lett. **2008**, 10, 1477–1480.

(25) Breese, A.; Cotterill, W. D.; Iqbal, M.; Livingstone, R. Reaction Between Some 6-Halogeno-2,2-dimethyl-,2,2,6-Trimethyl- and 2,2-Diaryl-2*H*-naphtho[1,2-*b*]pyrans and 1,1-Diphenylethene. *J. Chem. Res.* **1998**, *9*, 532–533.

(26) Luan, Y.; Sun, H.; Schaus, S. E. Iron-Catalyzed Rearrangements and Cycloaddition Reactions of 2*H*-Chromenes. *Org Lett.* **2011**, *13*, 6480–6483.

(27) The details of the DFT calculations are shown in the Supporting Information.

(28) Chen, G.; Gui, J.; Li, L.; Liao, J. Chiral Sulfoxide-Olefin Ligands: Completely Switchable Stereoselectivity in Rhodium-Catalyzed Asymmetric Conjugate Additions. *Angew. Chem., Int. Ed.* **2011**, 50, 7681–7685.

(29) Forrat, V. J.; Ramón, D. J.; Yus, M. First Catalytic Enantioselective Synthesis of the Cocaine Abuse Therapeutic Agent (S)-(+)-1-(4-{2-[Bis(4-fluorophenyl])methoxy]ethyl}-piperazin-1-yl)-2-phenyl-2-propanol. *Tetrahedron: Asymmetry* **2007**, *18*, 400–405.

(30) Braish, T. F.; Saddler, J. C.; Fuchs, P. L. Seven-Ring Annulation: A Linch-Pin Approach to a Tetracyclic Precursor of the Lathrane Diterpenes. J. Org. Chem. **1988**, 53, 3647–3658.

(31) Du, W.; Lai, J.; Tian, L.; Xie, X.; She, X.; Tang, S. Metal-Free Mizoroki–Heck Type Reaction: A Radical Oxidative Coupling Reaction of 2-Chloro-Dithiane with Substituted Olefins. *Chem. Commun.* **2014**, *50*, 14017–14020.

(32) Deutman, A. B. C.; Varghese, S.; Moalin, M.; Elemans, J. A. A. W.; Rowan, A. E.; Nolte, R. J. M. Slippage of a Porphyrin Macrocycle over Threads of Varying Bulkiness: Implications for the Mechanism of Threading Polymers through a Macrocyclic Ring. *Chem. – Eur. J.* **2015**, *21*, 360–370.

(33) Jabbar, M. A.; Shimakoshi, H.; Hisaeda, Y. Enhanced Reactivity of Hydrophobic Vitamin B12 Towards the Dechlorination of DDT in Ionic Liquid. *Chem. Commun.* **2007**, 1653–1655.

(34) Xu, S.; Gao, Y.; Chen, R.; Wang, K.; Zhang, Y.; Wang, J. Copper(I)-Catalyzed Olefination of N-Sulfonylhydrazones with Sulfones. *Chem. Commun.* **2016**, *52*, 4478-4480.

(35) Zhao, X.; Jing, J.; Lu, K.; Zhang, Y.; Wang, J. Pd-Catalyzed Oxidative Cross-Coupling of N-Tosylhydrazones with Arylboronic Acids. *Chem. Commun.* **2010**, *46*, 1724–1726.

(36) Wang, G.-Z.; Li, X.-L.; Dai, J.-J.; Xu, H.-J. AIBN-Catalyzed Oxidative Cleavage of gem-Disubstituted Alkenes with O_2 as an Oxidant. J. Org. Chem. 2014, 79, 7220–7225.

(37) Banciu, M. D.; Costea, C.; Draghici, C.; Banciu, A.; Mihaiescu, D.; Ciuculescu, D. Flow-vacuum Pyrolysis of 5-Methylene-5*H*-dibenzo[*a,d*]cycloheptene. *J. Anal. Appl. Pyrolysis* **2003**, *67*, 359–368.

(38) Taheri, A.; Lai, B.; Yang, J.; Zhang, J.; Gu, Y. Facile Synthesis of Densely Substituted Chroman Derivatives Through Brønsted Acid Ionic Liquid Catalyzed Three-Component Reactions of Aromatic Aldehydes, 1,1-Diarylethylenes and Nucleophiles. *Tetrahedron* 2016, 72, 479–488.